



The CASSISS Trial

Full Title	China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): A prospective, multi-center, randomized controlled trial (RCT)
Short Title	The CASSISS Trial
Version	1.0
Date	March 4 th , 2013
	Dr. Liqun Jiao
	Department of Neurosurgery and Interventional Neuroradiology
	Xuanwu Hospital
Principal	China International Neuroscience Institute
investigator	Capital Medical University
	Beijing, China
	Email: liqunjiao@sina.cn
	Telephone: +86-10-83199060
	Dr. Peng Gao
Trial coordinators	Dr. Tao Wang
coordinators	Xuanwu Hospital, Capital Medical University, Beijing, China
	<i>Dr. Daming Wang</i> Department of Neurosurgery, Beijing Hospital, Beijing, China, China
	Dr. Huangzhang Shi
	Department of Neurosurgery, the 1st Affiliated Hospital of Harbin Medical University, Harbin, China
	Dr. Tianxiao Li
Participating	Department of Intervention, Henan Provincial People's Hospital, Zhengzhou, China
centers	Dr. Zhenwei Zhao
	Department of Neurosurgery, Tangdu Hospital of Air Force Medical University, Xi'an, China
	Dr. Wei Wu
	Department of Neurology, Qilu Hospital of Shandong University, Ji'nan, China
	Dr. Yiling Cai
	Department of Neurology, PLA Strategic Support Force Characteristic Medical Center, Beijing, China

	<i>Dr. Weiwen He</i> Department of Neurosurgery, the 2nd affiliated Hospital of Guangzhou Medical University, Guangzhou, China
	<i>Dr. Long Yin</i> Tianjin Huanhu Hospital, Tianjin, China
	<i>Dr. Shengping Huang</i> Guangdong Province Hospital of Traditional Chinese Medicine, Guangzhou, China
Sponsor	Xuanwu Hospital, Capital Medical University
CRO	Tigermed Data Management Co., Ltd
Funding	Ministry of Health, People's Republic of China; Stryker Neurovascular Inc. (Fremont, CA, USA)

Protocol signature sheet

Name	Signature	Date
Department of Neurosurgery and Interventional Neuroradiology, China International Neuroscience Institute Xuanwu Hospital, Capital Medical	Dr. Liqun Jiao	
University, Beijing, China		

24	TABLE OF CONTENTS	
25	1. LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS	7
26	2. SUMMARY	10
27	3. INTRODUCTION AND RATIONALE	12
28	3.1 DESCRIPTION OF THE DISEASE	12
29	3.2 DESCRIPTION OF THE INTERVENTION	12
30	3.3 RELEVANCE FOR CLINICAL PRACTICE	12
31	3.4 Hypothesis and rationale	13
32	3.5 OBJECTIVES	13
33	3.5.1 Primary objective	13
34	3.5.2 Secondary objectives	14
35	4. STUDY DESIGN	15
36	5. STUDY POPULATION	17
37	5.1 POPULATION	17
38	5.2 CREDENTIALING OF THE PARTICIPATING CENTERS AND CENTER ELIGIBILITY	17
39	5.3 INCLUSION CRITERIA	18
40	5.4 Exclusion criteria	19
41	6. METHODS	22
42	6.1 PRIMARY OUTCOMES	22
43	6.2 SECONDARY OUTCOMES	22
44	6.3 DEFINITIONS OF OUTCOMES	22
45	6.4 DEFINITIONS OF OTHER PARAMETERS	24
46	6.4.1 Major vascular complications	24
47	6.4.2 Minor vascular complications	24
48	6.5 TREATMENT ASSIGNMENT	25
49	6.6 RANDOMIZATION AND NUMBERING	25
50	6.7 MEDICAL GROUP	25
51	6.7.1 Medical therapy	25
52	6.7.2 Management of risk factors	
53	6.7.3 Health education and lifestyle modification	
54	6.8 PTAS group	
55	6.8.1 PTAS procedure	
56	6.8.2 Rescue therapy for PTAS	
57	6.9 FOLLOW-UP SCHEDULE	
58	6.9.1 Baseline	
59	6.9.2 Procedure (for PTAS group)	

60	6.9.3 Discharge	30
61	6.9.4 30-day follow-up	31
62	6.9.5 1-year follow-up	31
63	6.9.6 2-year follow-up	32
64	6.9.7 3-year follow-up	33
65	6.10 CONSENT WITHDRAWAL	34
66	6.11 FOLLOW-UP OF SUBJECTS WITHDRAWN FROM TREATMENT ASSIGNMENT	34
67	6.12 LOST FOR FOLLOW-UP	34
68	6.13 STUDY COMPLETION AND POST-STUDY TREATMENT	35
69	6.14 PREMATURE TERMINATION OF THE STUDY	35
70	6.15 OUTCOME ASSESSMENT	35
71	7. SAFETY MONITORING	36
72	7.1 Adverse events (AE)	36
73	7.2 Serious adverse events (SAE)	36
74	7.2.1 Definition of SAE	36
75	7.2.2 SAE reporting	36
76	7.2.3 Management and follow-up of AEs/SAEs	36
77	8. DATA MANAGEMENT	38
78	8.1 Study Data Collection	38
79	8.2 DATA PROCESSING AND QUALITY CONTROL	38
80	8.3 Data storage	39
81	9. STATISTICAL ANALYSIS	40
82	9.1 ANALYSIS DATA SET	40
83	9.2 ANALYSIS CLOSE DATE	40
84	9.3 SAMPLE SIZE CALCULATION	40
85	10. STUDY COMMITTEES	41
86	10.1 Executive and Steering Committee	41
87	10.2 ETHICS COMMITTEE	41
88	10.3 DATA AND SAFETY MONITORING BOARD (DSMB)	41
89	10.4 CLINICAL OUTCOME COMMITTEE	41
90	10.5 IMAGING OUTCOME COMMITTEE:	41
91	11. ETHICAL AND ADMINISTRATIVE CONSIDERATIONS	43
92	11.1 REGULATORY AND ETHICAL COMPLIANCE	43
93	11.2 RECRUITMENT AND INFORMED CONSENT FORM	43
94	11.3 RESPONSIBILITIES OF THE INVESTIGATOR	43
95	11.4 PUBLIC DISCLOSURE AND PUBLICATION POLICY	43

96	12. REFERENCES	.44
97	13. APPENDIX	48
98	13.1 Barthel Index (BI)	. 48
99	13.2 Modified Rankin Scale (MRS)	. 50
100	13.3 NIH STROKE SCALE	. 51
101	13.4 MORI CLASSIFICATION	. 58
102	13.5 TICI PERFUSION CATEGORIES	. 59
103	13.6 ASITN/SIR COLLATERAL FLOW GRADING SYSTEM	. 60
104		

107 **1. LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS**

AE	Adverse Event
AHA	American Heart Association
ALT	Alanine transarninase
APTT	Activated Partial Thromboplastin Time
ASA	American Stroke Association
ASITN/SIR	American Society of Interventional and Therapeutic
	Neuroradiology/Society of Interventional Radiology
	(ASITN/SIR) Collateral Flow Grading System
AST	Aspartate aminotransferase
ATM	Atmosphere
BA	Basilar Artery
BMI	Body Mass Index
BUN	Blood Urea Nitrogen
DSMB	Data Safety and Monitoring Board
DWI	Diffusion-weighted Imaging
ECG	Electrocardiogram
CBF	Cerebral Blood Flow
CBV	Cerebral Blood Volume
Cr	Creatine
CRF	Case Report Form
CRP	C-reactive protein
СТ	Computed Tomography
СТА	Computed Tomography Angiography
CTP	Computed Tomography Perfusion
DSA	Digital Subtraction Angiography
DAPT	Dural Anti-Platelet Therapy
DWI	Diffusion-Weighted Imaging
EC	Ethics Committee, synonymous to Institutional Review
	Board (IRB) and Independent Ethics Committee (IEC)
EDC	Electronic Data Capture

FAS	Full Analysis Set
FBG	Fasting blood glucose
FIB	Fibrinogen
GCP	Good Clinical Practice
HDL	High-density Lipoprotein
HbA1c	Glycated Hemoglobin
ICA	Internal Carotid Artery
ICAS	IntraCranial Atherosclerotic Stenosis
ICF	Informed Consent Form
INR	International Normalized Ratio
IRB	Institutional Review Board
ITT	Intention To Treat
IVRS	Interactive Voice Response System
LDL	Low-density Lipoprotein
LOCF	Last Observed Carried Forward
MCA	Middle Cerebral Artery
MRA	Magnetic Resonance Angiography
mRS	Modified Rankin Scales
MTT	Mean Transit Time
NIHSS	National Institute of Health Stroke Scale
PI	Principle Investigator
PPS	Per-Protocol Set
PT	Prothrombin Time
PWI	Perfusion Weighted Imaging
RCT	Randomized Control Trial
PTAS	Percutaneous Transluminal Angioplasty and Stenting
SAE	Serious Adverse Event
SIT	Stroke In the Territory of symptomatic intracranial
	stenosis
Sponsor	The sponsor is the party that commissions the
	organization or performance of the research, for example
	a pharmaceutical company, academic hospital, scientific
	organization or investigator. A party that provides funding

	for a study but does not commission it is not regarded as
	the sponsor, but referred to as a subsidising party.
ТС	Total Cholesterol
TCD	TransCranial Doppler
TIA	Transient Ischemic Attack
TICI	Thrombolysis in Cerebral Infarction
ТТ	Thrombin Time
TTP	Time-to-Peak
USA	United States of America
VA	Vertebral Artery

111 **2. SUMMARY**

Title	China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): A prospective, multi-center, randomized controlled trial	
Objectives	To determine whether intracranial angioplasty and stenting with Gateway-Wingspan stent system adds benefit to medical therapy alone for preventing the primary outcome (stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery between 30 days through 1 year in patients with recent TIA or stroke caused by 70% to 99% stenosis of a major intracranial artery).	
Patient population	Patients with recent TIA or stroke caused by 70% to 99% stenosis of a major intracranial artery.	
Sample size	380 (ratio 1:1)	
Intervention	Random 1:1 allocation to medical therapy alone versus medical therapy plus intracranial angioplasty and stenting with Gateway-Wingspan stent system. Superiority is prospectively defined if the stenting arm has a significantly lower stroke or death rate.	
Study design	Prospective, open-label, multi-center, randomized controlled study.	
	Primary outcomes:	
	Stroke or death within 30 days after enrollment;	
	• Stroke in the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 year	
Main parameters	Secondary outcomes:	
/ Outcomes	 Disabling stroke or death beyond 30 days through 3 years in both arms; 	
	Complication rates associated with stenting procedures;	
	 Restenosis (>50%) related to stenting within a follow-up of 3 years; 	
	Any stroke, severe TIA, or cardiovascular events within a	

	follow-up of 3 years;
	 National Institutes of Health Stroke Scale (NIHSS), mRS, and Barthel index assessment within a follow-up of 3 years;
	The compliance rate of patients with regular medical therapy within a follow-up of 3 years;
	• Death rate in both arms within a follow-up of 3 years.
Follow-up schedule	Baseline, 30-day, 1-year, 2-year, and 3-year
	The primary and secondary outcomes are compared between the groups using log-rank test by ITT.
	An independent groups t-test or Wilcoxon rank test are used to compare the quantitative data between the groups.
Statistical	Chi-square test or Fisher exact probability method is used for categorical data between the groups.
analysis plan	Kaplan-Meier curves is used to show the incidence of outcomes over time.
	All statistical tests are performed by two-sided test. P- value less than 0.05 is considered as statistically significant.
	All the analyses are performed with the use of SAS software (SAS Institute).

122 **3. INTRODUCTION AND RATIONALE**

123

124 **3.1 Description of the disease**

125Stroke is one of the leading causes of death in China and confers a large burden and effort upon patients and health professionals.¹⁻³ In contrast to 126 Western countries, intracranial atherosclerotic stenosis (ICAS) is the most 127 128 common vascular lesion in patients with cerebrovascular disease, and is an important cause of ischemic stroke and future recurrent events in China.4-7 129 130 Patients with ICAS have long been considered to be at high risk of recurrent 131 stroke, which led to the development and wide use of percutaneous transluminal angioplasty and stenting (PTAS).⁸⁻¹² 132

133

134 **3.2 Description of the intervention**

135 In 2005, the Wingspan Stent system (Stryker Neurovascular, Fremont, CA, 136 USA) was approved under a Humanitarian Device Exemption by the US Food 137 and Drug Administration (FDA), and had been used to reduce the rate of recurrent ischemic events among patients with severe symptomatic ICAS.¹³⁻¹⁷ 138 139 However, the Stenting and Aggressive Medical Management for Preventing 140 Recurrent Stroke in Intracranial Stenosis trial (SAMMPRIS trial, ClinicalTrials.gov number, NCT00576693), as the first RCT,¹⁸ demonstrated 141 142 that aggressive medical management was superior to PTAS with the 143 Wingspan stent among patients with symptomatic severe ICAS, both because 144 the risk of early stroke after stenting was high (14.7%) and because the risk of 145 stroke with aggressive medical therapy alone was lower than expected 146 (5.8%).¹⁹

147

148 **3.3 Relevance for clinical practice**

149 Since the SAMMPRIS trial, concerns have emerged that outcomes seen in a 150 clinical trial setting may not be reproducible in non-RCT setting because of 151 demonstrated more optimal surgical outcomes, less complication rates in 152 high-volume centers, and good patient selection. The technical procedural 153 problem rate, including guidewire- or angioplasty-related hemorrhage, could 154 be minimized as more experienced operators overcome the learning curve for mastering the safety precautions of Wingspan stenting for ICAS.20-22 In the 155 156 post-SAMMPRIS era, several single or multi-center, registration studies in China,²³⁻²⁶ suggested lower risks of intracranial stenting for ICAS than those 157 reported for SAMMPRIS.¹⁹ 158

Second, poor patient selection may increase the peri-operative risks and bias
 the outcome favoring medical treatment. In the stenting arm of the
 SAMMPRIS trial, more than 50% (115/224) of patients had a time interval

from qualifying event to randomization of less than 7 days.¹⁹ Short interval or early stenting intervention may confer a higher risk of cerebral vascular event, including thromboembolic events, perforator stroke,²⁷ or even hemorrhagic transformation. Also, in the SAMMPRIS trial, 22.8% of recruited patients had perforators stroke only, and those patients may not benefit from stenting in addition to medical therapy. Ideally, stenting may be considered for eligible patients based on poor collaterals and medical futility.²⁸

Third, intracranial stenting involves a trade-off between a higher short-term perioperative risk in exchange for a lower long-term risk of stroke. In the SAMMPRIS trial the stenting group, mostly due to periprocedural complication, had more disabling or fatal stroke within 30 days than that in medical group (7.1% vs 1.8%), whereas the stenting group had less disabling or fatal stroke beyond 30 days than that in medical group (2.2% vs 6.2%).¹⁹

175 The choice for ICAS treatment between medical therapy and stenting remains 176 incompletely settled, at least for certain high-volume centers and for certain 177 patient groups in a Chinese population. Furthermore, the recurrent stroke risk in the real world remains high despite maximal medical therapy.²⁹ Since the 178 179 SAMMPRIS trial, an ever-increasing number of PTAS procedures surged 180 beyond guidelines due to increased demand for ICAS treatment in China. The 181 research community has maintained interest in tackling this important cause 182 of stroke. Intracranial stenting with Wingspan is still awaiting a safe landing.30,31 183

184

185 **3.4 Hypothesis and rationale**

186 It may be hypothesized that the clinical superiority observed in carefully 187 selected patients in high-volume center who received medical therapy had 188 diminished, making stenting a more favorable treatment strategy in 189 comparison. As compared to the design of the SAMMPRIS trial, we thus feel 190 that there is the need for a refined randomized trial reevaluating the role of 191 stenting for ICAS. In the CASSISS trial, patients in both treatment groups 192 have been followed up for 3 more years to establish whether early benefit in 193 the medical group would persist over longer follow-up, or whether the medical 194 group would have a high incidence of late stroke that would eliminate the 195 early efficacy gap between groups.

196

197 **3.5 Objectives**

198 **3.5.1 Primary objective**

To determine whether PTAS (using the Gateway PTA balloon catheter and
 Wingspan Stent System, Stryker, Fremont, CA, USA) combined with medical
 therapy is superior to medical therapy alone for preventing the primary

202 outcome (stroke or death within 30 days after enrollment, or stroke in the 203 territory of the symptomatic intracranial artery between 30 days through 1 204 year in patients with recent TIA or non-disabling stroke caused by 70% to 205 99% stenosis of a major intracranial artery).


206

- 207 **3.5.2 Secondary objectives**
- 208 To compare outcomes between groups in terms of:
- Disabling stroke or death beyond 30 days through 3 years;
- Complication rates associated with stenting procedures;
- Restenosis (>50%) related to stenting within a follow-up of 3 years;
- Any stroke, severe TIA, or cardiovascular events within a follow-up of 3 213 years;
- National Institutes of Health Stroke Scale (NIHSS), mRS, and Barthel index assessment within a follow-up of 3 years;
- The compliance rate of the patients with regular medical therapy within a follow-up of 3 years;
- Death rate in both arms within a follow-up of 3 years.

220 **4. STUDY DESIGN**

221 This trial is a prospective, multi-center, open-label, randomized control trial 222 that will be conducted in 8 high-volume centers in China Mainland. Patients 223 who meet inclusion criteria are randomized (1:1) to medical therapy alone or 224 to PTAS plus medical therapy. This trial aims to enroll 380 cases. This sample 225 size is large enough to result in acceptable data about safety and efficacy. At 226 each investigational site, the local treating team will consist of at least a 227 neurologist, a neurosurgeon, a neuroradiologist, and a research coordinator. 228 The local treating team conducted enrollment after they reviewed the 229 qualification of each patient. Patients assigned to the medical group will be 230 discharged without further intervention. They will be administered aspirin 100 231 mg plus clopidogrel 75 mg per day for 90 days (aspirin alone per day 232 thereafter). Medical therapy will be identical in both arms and will be similar to 233 the previously-described risk factor management for the SAMMPRIS trial and AHA/ASA guidelines.^{19 32} Patients assigned to the PTAS group will receive 234 235 PTAS within 3-5 business days after enrollment. All patients will be followed-236 up in outpatient consultation or by telephone contact with the site 237 investigators at 30-day, 1-year, 2-year, and 3-year marks until the last patient 238 enrolled finishes 3-year follow-up or if patients die before the close-out visit 239 (see flow chart).

- 241 Expected enrollment initiation date: March, 2014
- 242 Expected enrollment completion date: March, 2017
- Expected study end date: March, 2020
- 244



250 **5. STUDY POPULATION**

251

5.1 Population

Patients with recent TIA or stroke caused by 70% to 99% stenosis of a major
intracranial artery. The stenotic degree will be determined on catheter
angiogram using the criteria of the Warfarin-Aspirin Symptomatic Intracranial
Disease Study [WASID]³³).

257

5.2 Credentialing of the participating centers and center eligibility

259 Centers are required to have a team consisting of a neurologist, a 260 neurosurgeon, a neuroradiologist, and a research coordinator. The 261 randomized trial will not begin until the clinical results of the participating 262 centers have been certified. All the centers who are interested in this trial will 263 perform a competitive registration study of recruiting a consecutive 100 PTAS 264 as a pre-clinical trial within a duration of 8 to 10 months. Certification will be 265 achieved by participating centers, whose clinical results are audited by means 266 of a validated selection process. Participating centers meet the following 267 criteria will be included in the randomized trial: 1) the annual volume of the 268 cases treated with intracranial stenting for ICAS over the past three years was 269 more than 30; 2) within the lead-in phase period of eight months, more than 270 five cases will be performed by a single principal operator; 3) less than 15% 271 stroke or death rate within 30 days after the revascularization procedure of 272 the qualifying lesion.

There will be 10 high-volume candidate sites (all tertiary hospitals), involved in a competitive registration study of recruiting a combined total of 100 consecutive patients treated with PTAS:

276

Table: 10 candidate enrollment sites

#	Sites
1	Xuanwu Hospital, Capital Medical University, Beijing, China
2	The 1st Affiliated Hospital of Harbin Medical University, Harbin, China
3	Henan Provincial People's Hospital, Zhengzhou, China
4	Tangdu Hospital of Air Force Medical University, Xi'an, China
5	Beijing Hospital, Beijing, China
6	Qilu Hospital of Shandong University, Ji'nan, China
7	PLA Strategic support Force Characteristic Medical Center, Beijing,

	China
8	The 2nd affiliated Hospital of Guangzhou Medical University, Guangzhou, China
9	Tianjin Huanhu Hospital, Tianjin, China
10	Guangdong Province Hospital of Traditional Chinese Medicine, Guangzhou, China

278 **5.3 Inclusion criteria**

279 Eligible patients aged between 30 and 80 years; intracranial arterial 1. 280 stenosis related to the following non-atherosclerotic factors will be not be 281 considered: arterial dissection, moya-moya disease; vasculitic disease; 282 herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; 283 any other intracranial infection; any intracranial stenosis associated with 284 cerebrospinal fluid pleocytosis; radiation-induced vasculopathy; 285 fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign 286 angiopathy of central nervous system; postpartum angiopathy; suspected 287 vasospastic process, and suspected recanalized embolus;

- Symptomatic intracranial stenosis: presented with transient ischemic
 stroke (TIA) or stroke within the past 12 months attributed to 70%-99%
 stenosis of a major intracranial artery (ICA, MCA [M1], vertebral artery, or
 basilar artery [BA]);
- 292 3. Degree of stenosis: 70%–99%; stenosis degree must be confirmed by
 293 catheter angiography for enrollment in the trial;
- 4. Remote infarctions on MRI scan, which can be accounted for by the
 occlusion of the terminal cortical branches or hemodynamic compromise
 (perforator occlusion excluded). Infarction due to perforators occlusion is
 defined as basal ganglia or brainstem/thalamus infarction related with M1
 or BA stenosis;
- 299 5. Expected ability to deliver the stent to the lesion;
- All the patients should be performed with stenting beyond a duration of
 three weeks from the latest ischemic symptom onset;
- 302 7. No recent infarctions identified on MRI (indicated as high signals on DWI
 303 series) upon enrollment;
- 8. No massive cerebral infarction (>1/2 MCA territory), intracranial
 hemorrhage, epidural or sub-dural hemorrhage, and intracranial brain
 tumor on CT or MRI scan;
- 307 9. mRS scale score of <=2;

- 308 10. Target vessel reference diameter must be measured to be 2.00 mm to
 309 4.50 mm; target area of stenosis is <=14 mm in length;
- 11. No childbearing potential or has a negative pregnancy test within the past
 one week prior to study procedure; female patients had normal menses in
 the last 18 months;
- 12. Patient is willing and able to return for all follow-up visits required by theprotocol;
- 315 13. Patients understand the purpose and requirements of the study and have316 signed informed consent form.
- 317

318 **5.4 Exclusion criteria**

- Refractory to general anesthesia; not able to be overcome by pre treatment with medical therapy
- 321 **2**. Any condition that precludes proper angiographic assessment
- 322 **3.** Tandem extracranial or intracranial stenosis (70%–99%) or occlusion that 323 is proximal or distal to the target intracranial lesion
- Bilateral intracranial VA stenosis of 70%–99% and uncertainty about
 which lesion is symptomatic (for example, if patient has pon, midbrain,
 temporal and occipital symptoms)
- 5. Presence of a previously placed intravascular stent or graft in the ipsilateral distribution within 30 days
- Brevious treatment of target lesion with a stent, angioplasty, or other
 mechanical device, or plan to perform staged angioplasty followed by
 stenting of target lesion
- 332 7. Severe vascular tortuosity or anatomy that would preclude the safe
 333 introduction of a guiding catheter, guiding sheath or stent placement
- 8. Plan to perform concomitant angioplasty or stenting of an extracranial
 vessel tandem to an ipsilateral intracranial stenosis
- 336 9. Presence of intraluminal thrombus proximal to or at the target lesion
- 10. Any aneurysm proximal to or distal to intracranial stenotic artery
- 11. Intracranial tumors or any intracranial vascular malformations
- 339 12. Computed tomographic or angiographic evidence of severe calcification340 at target lesion
- 13. Thrombolytic therapy within 24 hours before enrollment
- 342 14. Evolving stroke or progressive neurologic signs within 24 hours before343 enrollment

	344 345 346	15.	Stroke of sufficient size (>5 cm on CT or MRI) to place patient at risk of hemorrhagic transformation during the procedure; hemorrhagic transformation of an ischemic stroke within the past 15 days
	347 348	16.	Previous spontaneous intracerebral (parenchymal) or other intracranial (subarachnoid, subdural, or epidural) hemorrhage within 30 days
ć	349	17.	Untreated chronic subdural hematoma >5 mm in thickness
	350 351 352 353	18.	Other cardiac sources of emboli such as left ventricular aneurysms, intracardiac filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcified aortic stenosis, endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm, left atrial myxoma
	354	19.	Myocardial infarction within previous 30 days
	355 356 357	20.	Chronic atrial fibrillation; any episode of paroxysmal atrial fibrillation within the past six months, or history of paroxysmal atrial fibrillation requiring chronic anticoagulation
	358 359	21.	Intolerance or allergic reaction to any of the medical therapy, including aspirin, clopidogrel, heparin, and local or general anesthetics
	360 361 362	22.	History of life-threatening allergy to contrast medium. If not life threatening and can be effectively pre-treated, patient can be enrolled at physicians' discretion
	363	23.	Recent gastrointestinal bleed that would interfere with antiplatelet therapy
	364 365 366 367 368 369 370 371 372 373	24.	Active bleeding diathesis or coagulopathy; active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets count <125,000, hematocrit <30, Hgb <10 g/dl, uncorrected INR >1.5, bleeding time >1 minute beyond upper limit normal, or heparin-associated thrombocytopenia that increases the risk of bleeding, uncontrolled severe hypertension (systolic BP>180mm hg or diastolic BP>115mm hg), severe liver impairment (AST or 25. ALT >3 times normal, cirrhosis), creatinine >265.2 mmol/l (unless on dialysis). Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 90 days after enrollment
	374	25.	Indication for warfarin or heparin beyond enrollment (exceptions allowed
	375 376		for use of systemic heparin during stenting procedure or subcutaneous heparin for deep venous thrombosis prophylaxis while hospitalized)
	377 378	26.	Inability to understand and cooperate with study procedures or sign informed consent
	379 380	27.	Severe dementia or psychiatric problems that prevent the patients from following an outpatient program reliably

381 28. Pregnancy or of childbearing potential and unwilling to use contraception382 for the duration of this study

383 29. Actively participating in another drug or device trial that has not completed384 the required protocol follow-up period

386 **6. Methods**

387

388 6.1 Primary outcomes

- Stroke or death within 30 days after enrollment;
- Stroke in the territory of the symptomatic intracranial artery (SIT) between
 30 days and 1 year

392

393 **6.2 Secondary outcomes**

- Disabling stroke or death beyond 30 days through 3 years in both arms;
- Complication rates associated with stenting procedures;
- Restenosis (>50%) related to stenting within a follow-up of 3 years;
- Any stroke, severe TIA, or cardiovascular events within a follow-up of 3
 years;
- National Institutes of Health Stroke Scale (NIHSS), mRS, and Barthel
 index (BI) assessment within a follow-up of 3 years;
- The compliance rate of the patients with regular medical therapy within a 402 follow-up of 3 years;
- Death rate in both arms within a follow-up of 3 years.

404

405 **6.3 Definitions of outcomes**

- Stroke is defined as the rapid loss of brain functions due to disturbance in the blood supply to the brain that persists beyond 24 hours. Stroke is diagnosed by an independent outcome committee which is composed with experienced neurologists. They will collect additional key neuroimages (CT or MR scans) as adjunct evidence for outcome classification of ischemic or hemorrhagic stroke;
- 412
 413 Ischemic stroke is defined as a new focal neurological deficit of sudden 413 onset lasting at least 24 hours that is not associated with a hemorrhage 414 on brain CT or MRI. Ischemic strokes are further classified by the 415 neurologic adjudicators as being either in or out of the territory of the 416 qualifying artery;
- 417 3. Hemorrhagic stroke is defined as parenchymal, sub-arachnoid, or intra 418 ventricular hemorrhage detected by CT or MRI that is associated with new
 419 neurological signs or symptoms lasting >24 hours or a seizure;
- 420 **4**. **Death**, any of the following criteria:

- 421 a) Procedure-related deaths, including those related to a complication 422 of the procedure or treatment for a complication of the procedure.
- b) Death to due to cardiac cause, e.g., myocardial infarction, cardiac
 tamponade, and worsening heart failure
- 425 c) Death of other cause (e.g., malignancy, trauma and suicide)
- 426 d) Sudden or unwitnessed death
- 427 e) Death of unknown cause
- 428 5. Disabling stroke is defined by any of the following:
- 429a) a modified Rankin score of 3 or more, on a scale of 0 to 6, with
higher scores indicating greater disability;
- 431 b) an increase in at least one mRS category from an individual's pre432 stroke baseline
- 433 c) a score on the composite National Institutes of Health Stroke Scale
 434 (NIHSS) of 7 or more, on a scale of 0 to 42, with higher scores
 435 indicating more severe deficits;
- d) an increase in at least 4 NIHSS scales from pre-stroke baseline.
- 6. Complication rates associated with stenting procedures: refer perforator
 occlusion, guidewire perforation, artery-to-artery embolism, stent
 thrombosis, or reperfusion hemorrhage within 72 hours after PTAS
 procedures.
- Restenosis rate: if patients have follow-up vascular imaging, the imaging modality will be recorded, in addition to the percent stenosis of the target lesion. Re-stenosis is defined as 50% narrowing or greater irrespective of symptoms.
- 8. TIA: duration of a focal or global neurological deficit <24 h, any variable
 neuroimaging does not demonstrate a new hemorrhage or infarction;
- 447 9. Severe TIA refers to rapidly developed clinical signs of focal or global
 448 disturbance of cerebral function lasting longer than 10 minutes but fewer
 449 than 24 hours, without apparent nonvascular cause.
- 450 10. Cardiovascular events: refer a class of events that is related to stenting or
 451 medical therapy, which includes coronary artery diseases (CAD) such as
 452 angina and myocardial infarction.
- 453 **11.** BI, mRS and NIHSS: please refer the appendix 12.1, 12.2 and 12.3.
- 454 12. Compliance of drug: patients will be contacted at 30-day, 1-year, 2-year
 455 and 3-year after enrollment, to gather information regarding the use of
 456 anti-platelet drugs, changes in prescribed drugs, medical condition and
 457 quality of life.

458		a)	very good, 80% - 120%;
459		b)	good, 60% - 79%;
460		c)	fair, 40% - 59%;
461		d)	poor, < 40%.
462			
463			
464	6.4	Defini	itions of other parameters
465	6.4	.1 Majo	or vascular complications
466 467	1.		neurovascular death: e.g., trauma, suicide, malignancy, or ovascular mortality;
468 469	2.	-	vascular complication: e.g., aortic dissection, aortic rupture, or us rupture;
470 471 472 473	3.	perfor irreve	es site of access-related vascular injury (dissection, stenosis, ration, rupture, arteriovenous fistula, pseudoaneurysm, hematoma, rsible nerve injury, or percutaneous closure device failure) leading to , life-threatening or major bleeding, or neurological impairment;
474 475	4.		cerebral embolism from a vascular source requiring surgery or /ascular intervention or irreversible neurological damage;
476 477 478	5.	sympt	new ipsilateral lower extremity ischemia documented by patient toms, physical examination, and/or decreased or absent blood flow ver extremity angiogram;
479	6.	surge	ry for access site-related nerve injury;
480	7.	perma	anent access site-related nerve injury.
481			
482	6.4	.2 Mino	or vascular complications
483 484 485 486	1.	perfor or pe	es site of access-related vascular injury (dissection, stenosis, ration, rupture, arteriovenous fistula, pseudoaneurysm, hematoma, ercutaneous closure device failure) not leading to death, life- rening or major bleeding, or neurological impairment;
487 488	2.		cerebral embolism treated with mechanical thrombectomy not ing in irreversible neurological damage;
489 490	3.	•	nplanned endovascular stenting or surgical intervention not meeting iteria for a major vascular complication;
491 492	4.		ular repair: e.g., ultrasound-guided compression or injection lization, transcatheter embolization or stent-graft;
493	5.	Percu	taneous closure device failure.

494 **6.5 Treatment assignment**

Eligible patients will be enrolled with their baseline data entered into a webbased database system. Patients will be randomized (1:1) to medical therapy alone or medical therapy plus stenting using Wingspan. There will be no blinding. When a patient is included for participation, site investigator will be informed. The patients will be excluded from the ITT analysis if they sign the ICF while they don't meet the criteria of inclusion and exclusion after central image Corelab adjudication.

A summary will be made of patients who are randomized to PTAS group but do not undergo surgery, and the patients who are randomized to medical therapy but receive surgery. Compliance will be assessed by the investigator at each visit using information provided by the care-giver or patients themselves. This information should be recorded in the source document at each visit.

508

509 **6.6 Randomization and numbering**

510 A central randomization system, IVRS (Interactive Voice Response System, 511 Clinicalsoft Company Limited, Beijing, China; http://ivr.clinicalsoft.cn) will be 512 used for patient randomization. Each patient has its unique ID number (center 513 number plus screening order number) in this trial. This center number will be 514 assigned to each participating center. Once the patients or their legal 515 representatives sign the informed consent form (ICF) at each center, they will 516 be assigned with a screening order number. At each center, the screening 517 order number will be in order of the patients' enrollment (e.g., 001, 002, 003 518 and so on).

519

520 6.7 Medical group

521

522 Patients randomized to medical group will received medical therapy and be 523 discharged without further intervention.

524

525 6.7.1 Medical therapy

526 Medical therapy will be identical in both arms and will be similar to the 527 previously described risk factor management for the SAMMPRIS trial. In brief, 528 it includes both aspirin 100 mg plus clopidogrel 75 mg per day for 90 days 529 (aspirin 100 mg alone per day thereafter) and management of risk factors.

530 The drugs used in the trial are commercially available in China. Several 531 generic aspirin or clopidogrel are available and allowed to be used. Medical 532 therapy regimen, including DAPT and statin will be purchased by the patients 533 or their family member, who later received various degrees of reimbursement 534 from the Chinese social security system.

535

536 **6.7.2 Management of risk factors**

Risk factor control is based on the 2011 AHA/ASA guidelines³² and the 537 538 SAMMPRIS¹⁹ trial protocol. Medical management of risk factors consists of 539 normalizing low-density lipoprotein (LDL-C) (statins, target LDL-C <2.58 540 mmol/l [100 mg/dl]), hypertension (systolic pressure <140 mmHg and a 541 diastolic pressure <90 mmHg), glucose disorder (in diabetic patients, 542 hemoglobin A1c [HbA1c] will be checked at enrollment and during each 543 clinical visit with a target level of <6.5%), and lifestyle modification. Intensive 544 management of risk factors is applicable to all the included patients (e.g., 545 hypertension, lipid disorder, diabetes mellitus, overweight, obesity, physical 546 inactivity, and cigarette smoking).

547

548 6.7.3 Health education and lifestyle modification

- 549 1. Health education and lifestyle modification: quit smoking, moderate-550 intensity physical exercises (at least 3 times per week for 30 min per 551 session).
- 552 **2.** Obesity: BMI should be maintained below 25 kg/m². Weight reduction is 553 associated with a lowering in BP and may thereby reduce stroke risk.

554

555

556 **6.8 PTAS group**

557

558 Patients randomized to PTAS group are to be scheduled for surgery within 559 three to five business days after enrollment. The study protocol requires that 560 the stenting procedure be performed by a qualified operator at each site.

561 6.8.1 PTAS procedure

562 Patients randomized to stenting will be placed on DAPT (aspirin, 100 mg daily 563 and clopidogrel 75 mg daily) for 3-5 consecutive days before the procedure. 564 No loading dose will be allowed. The study protocol requires that the PTAS 565 procedure is typically performed under general anesthesia by a credentialed 566 interventionist who should be the primary operator. The procedure is typically 567 performed via a transfemorally placed 6F-long sheath or guiding catheter. The 568 stenotic lesion is primarily crossed with a standard 0.014" microcatheter 569 microwire system under high magnification fluoroscopic roadmap control. 570 Once across the lesion, the microcatheter is exchanged over a 300-cm,

571 0.014" microwire for a Gateway balloon catheter. After angioplasty, the 572 balloon catheter is exchanged for a Wingspan stent delivery system and the 573 self-expanding Wingspan stent is deployed across the stenosis. If the residual 574 stenosis after inserting the Wingspan stent is >50%, the study protocol allows 575 for postdilation with a new balloon catheter. The protocol required frequent 576 measurements of blood pressure during the procedure and at least 1 577 measurement every half an hour during the next 24 hours while the patient is 578 monitored. The patient will be continued on aspirin, 100 mg daily, and 579 clopidogrel, 75 mg daily, for the next 90 days and subsequently on aspirin 580 alone. Risk factor control should be applied thereafter.

- 581
- 582 6.8.2 Rescue therapy for PTAS
- If the residual stenosis is >50% after the primary Wingspan placement,
 study protocol allows for the postdilation with a new balloon catheter to
 achieve better angioplasty outcome.
- 5862.If the initial Wingspan stent could not be delivered to the target lesion, the587interventionalist can try to deliver a second Wingspan stent.
- 5883. If the second Wingspan stent cannot be delivered to the target lesion, the589interventionalist has the following options: a) angioplasty alone with590Gateway balloon catheter; b) using non-Wingspan stent; c) procedure591aborted.
- 4. If an ischemic stroke occurs or an intraluminal thrombus develops during
 the procedure, the interventionalist or stroke neurologist (if available)
 should administrate appropriate treatment. This may include intravenous
 or intraarterial use of thrombolytic therapy, e.g., glycoprotein IIb-IIIa
 Inhibitor (Tirofiban).
- 597 5. If a major dissection, other occlusive complication, or stent misplacement 598 occurs that requires placement of a second Wingspan stent, this may be 599 done as a rescue procedure. In the meantime, neuro ICU will provide 600 reservations to deal with patients with serious complications.
- 601

602 **6.9 Follow-up schedule**

603 Clinical assessment of patients will be conducted in outpatient consultation or 604 by telephone contact with the site investigators at 30-day, 1-year, 2-year, and 605 3-year or if the patients died before the close-out visit. At each follow-up visit, 606 patients will be examined by study physicians who also manage the patients' 607 vascular risk factors. Imaging assessment will be achieved by head MRI, CTA, 608 MRA, or DSA at each visit if possible.

6	1	0
---	---	---

Table: follow-up schedule

	In-hospital			Follow-up (Paper-based CRF)			
	Baseline	Procedure	Discharge	30- day	1- year	2- year	3- year
ICF	×						
In-/Exclusion criteria	×						
Demographics	×						
Medical history	X						
Physical exam	×			×	×	×	×
Neurological status	•	•			•	•	•
NIHSS	×	×	×	X	×	×	×
mRS	×	×	×	×	X	×	X
Barthel Index	×	×	×	×	X	X	X
Lab test	×				X	X	X
Neuro-imaging	•	•			•	•	•
CT/MRI (DWI)	×				×	×	×
TCD/CTA/MRA	×				X	×	×
CTP/PWI	×	×			×	×	×
DSA	×	×			×	×	×
Medication	×			×	×	×	×
AE/SAE		X	×	×	X	X	X

611

- 613 **6.9.1 Baseline**
- 614 At baseline, the following parameters should be documented:
- 615 I. Date of ICF
- 616 II. Demographics
- 617 III. Medical history
- 618 a. Present history
- b. Previous history, e.g., hypertension, diabetes, lipid disorder,
 coronary and peripheral artery disease, smoking and alcohol
 abuse, etc.
- 622 IV. Clinical status
- 623 a. Physical examination
- 624b. Vital signs: blood pressure, pulse rate, respiratory rate and body625temperature
- 626 c. ECG
- 627 d. BMI
- 628 V. Neurological status
- 629 a. NIHSS
- 630 b. mRS

631		c. Barthel Index
632	VI.	Lab test
633		a. Routine blood test
634		b. Liver function: e.g., ALT, AST, etc.
635		c. Renal function: e.g., Cr, BUN, etc.
636 637		 Renal damage: proteinuria (according to site's preference and facilities)
638		e. FBG and HbA1c
639		f. Lipid level: LDL, HDL and TC
640		g. Blood coagulation test: APTT, PT, TT, FIB, INR, etc.
641		h. Inflammation markers: CRP
642		i. Pregnancy test
643	VII.	Neuro-imaging
644		a. Cranial CT/MR (DWI)
645		b. TCD/CTA/MRA
646		c. CTP/PWI parameters: CBF, CBV, MTT and TTP
647		d. DSA
648		
649	6.9.2	Procedure (for PTAS group)
650	During	g the procedure, the following parameters should be documented:
651	I.	Date of the procedure
652		a. delayed procedure: beyond 5 business day after enrollment
653		b. procedure on time: within 5 business day after enrollment
654	II.	Operator of the procedure
655	III.	Anesthesia: general or local
656	IV.	Morphological characteristics of the lesion on DSA
657		a. side: right or left
658		b. size: diameter and length (mm)
659		c. location: M1, BA, ICA or VA
660		d. stenotic degree (%) determined using the WASID criterion 33
661		e. Mori classification: type A, B or C ³⁴ (Appendix 12.4)
662		f. TICI perfusion categories ³⁵ (Appendix 12.5)

663		g. ASITN/SIR collateral flow grading system ³⁵ (Appendix 12.6)
664	V.	Type of procedures
665		a. angioplasty plus stent placement
666		b. angioplasty alone
667		c. none
668	VI.	Angioplasty balloon
669		a. size: diameter and length (mm)
670		b. type: Gateway or others
671		c. number: 1 or more
672	VII.	Stent delivered
673		a. size: diameter and length (mm)
674		b. type: Wingspan or others
675		c. number: 1 or more
676	VIII.	Residual stenosis (%)
677	IX.	Use of post-dilation:
678		a. yes or no
679		b. if yes, type and size of the balloon used
680		c. inflation pressure (atm)
681		d. residual stenosis after post-dilation
682	Χ.	Rescue therapy
683	XI.	Post-PTAS neurological status
684		a. NIHSS
685		b. mRS
686		c. Barthel Index
687	XII.	AE/SAE
688		
689	6.9.3	Discharge
690	Before	e discharge, the following parameters should be documented:
691	I.	Neurological status
692		a. NIHSS
693		b. mRS
694		c. Barthel Index

695	II. AE/SAE
696	
697	6.9.4 30-day follow-up
698	At 30-day follow-up, the following parameters should be documented:
699	I. Clinical status
700	a. Physical examination
701 702	 b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature
703	c. ECG
704	d. BMI
705	II. Neurological status
706	a. NIHSS
707	b. mRS
708	c. Barthel Index
709	III. Medication
710	IV. AE/SAE
711	
712	6.9.5 1-year follow-up
713	At 1-year follow-up, the following parameters should be documented:
714	I. Clinical status
715	a. Physical examination
716 717	 b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature
718	c. ECG
719	d. BMI
720	II. Neurological status
721	a. NIHSS
722	b. mRS
723	c. Barthel Index
724	III. Lab test
725	a. Routine blood test
726	b. Liver function: e.g., ALT, AST, etc.

727	c. Renal function: e.g., Cr, BUN, etc.
728 729	 Renal damage: proteinuria (according to site's preference and facilities)
730	e. FBG and HbA1c
731	f. Lipid level: LDL, HDL and TC
732	g. Blood coagulation test: APTT, PT, TT, FIB, INR, etc.
733	h. Inflammation markers: CRP
734	IV. Neuro-imaging
735	a. Cranial CT/MR (DWI)
736	b. TCD/CTA/MRA
737	c. CTP/PWI parameters: CBF, CBV, MTT and TTP
738	d. DSA
739	V. Medication
740	VI. AE/SAE
741	
742	6.9.6 2-year follow-up
743	At 2-year follow-up, the following parameters should be documented:
744	I. Clinical status
745	a. Physical examination
746 747	 b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature
748	c. ECG
749	d. BMI
750	II. Neurological status
751	a. NIHSS
752	b. mRS
753	c. Barthel Index
754	III. Lab test
755	a. Routine blood test
756	b. Liver function: e.g., ALT, AST, etc.
757	c. Renal function: e.g., Cr, BUN, etc.
758 759	 Renal damage: proteinuria (according to site's preference and facilities)

760	e. FBG and HbA1c
761	f. Lipid level: LDL, HDL and TC
762	g. Blood coagulation test: APTT, PT, TT, FIB, INR, etc.
763	h. Inflammation markers: CRP
764	IV. Neuro-imaging
765	a. Cranial CT/MR (DWI)
766	b. TCD/CTA/MRA
767	c. CTP/PWI parameters: CBF, CBV, MTT and TTP
768	d. DSA
769	V. Medication
770	VI. AE/SAE
771	
772	6.9.7 3-year follow-up
773	The following parameters should be documented:
774	I. Clinical status
775	a. Physical examination
776	b. Vital signs: blood pressure, pulse rate, respiratory rate and body
777	temperature
778	c. ECG
779	d. BMI
780	II. Neurological status
781	a. NIHSS
782	b. mRS
783	c. Barthel Index
784	III. Lab test
785	a. Routine blood test
786	b. Liver function: e.g., ALT, AST, etc.
787	c. Renal function: e.g., Cr, BUN, etc.
788	d. Renal damage: proteinuria (according to site's preference and
789	facilities)
790	e. FBG and HbA1c
791	f. Lipid level: LDL, HDL and TC

- g. Blood coagulation test: APTT, PT, TT, FIB, INR, etc.
- 793 h. Inflammation markers: CRP
- 794 IV. Neuro-imaging
- 795 a. Cranial CT/MR (DWI)
- 796 b. TCD/CTA/MRA
- c. CTP/PWI parameters: CBF, CBV, MTT and TTP
- 798 d. DSA
- 799 V. Medication
- 800 VI. AE/SAE
- 801

802 6.10 Consent withdrawal

Patients may voluntarily withdraw consent to participate in the study for any reason at any time. Consent withdrawal occurs only when a patient: 1) does not want to participate in the study anymore; 2) or does not want any further visits or assessments; 3) or does not want any further study-related contacts.

When a patient withdraws consent, the investigator is required to determine the primary reason for this decision and record this information. Further attempts to contact the patient are not allowed unless safety efficacy require follow-up. After withdrawal, patients will not be replaced by others and their randomized ID number will not be re-used.

812

813 6.11 Follow-up of subjects withdrawn from treatment assignment

Some cases may withdraw from treatment assignment. Since the statistical analysis is planned for ITT principle, they will be analyzed in the group that they were originally allocated to.

817

818 6.12 Lost for follow-up

819 For patients whose status are unclear because they fail to appear for study 820 visits without stating an intention to withdraw, the investigator should show 821 "due diligence" by contacting the patient, family or family physician as agreed 822 in ICF and by documenting in the source documents steps taken to contact 823 the patient, e.g., dates of telephone calls, registered letters, etc. Lost for 824 follow-up could be accounted by no reply although try to contact the cases 825 three times or more. A patient should not be formally considered lost to follow-826 up until his/her scheduled end of study visit would have occurred.

828 6.13 Study completion and post-study treatment

At the end of the study visit, the investigator should provide follow-up medical care for all patients who are prematurely withdrawn from the study or refer them for appropriate ongoing care. When the patient has completed all scheduled study assessments, the investigator is required to inform to record the patient completion in the EDC system.

834

835 **6.14 Premature termination of the study**

836 During the trial, AEs or SAEs will be reported to DSMB. The DSMB will 837 monitor SAEs, major safety events, device and procedure failures and any 838 device-related adverse events. In the current trial, SAEs mainly refer disabling 839 stroke, symptomatic intracranial hemorrhage or death within 1 year after 840 enrollment and all-cause death within a follow-up 3 years. The stopping rules 841 will be developed by DSMB and the advices of DSMB will be sent to the 842 executive and steering committee of the study. The Executive and Steering 843 Committee will be responsible for informing the EC whether the advices are 844 fully implemented or not.

845

846 **6.15 Outcome assessment**

This is a multicenter phase IV RCT with open-label treatment and blinded outcome assessment. Outcome assessment will be sent to an independent Outcome Committee. The committee is composed of experienced neurologists who are not involved in the study, will be blinded to the treatment assignment. All the outcome will be adjudicated by the outcome committee, and a consensus will be reached by a third clinician in case of discrepancies.

853

854

855

857 **7. SAFETY MONITORING**

858 **7.1 Adverse events (AE)**

AE is defined as any unfavorable and unintended sign, symptom or disease that occurs to a subject while enrolled in a clinical investigation, whether or not considered related to the study intervention or device. Medical conditions that exist at study enrollment are not considered an AE unless condition worsens after use of the study intervention or device.

864

865 **7.2 Serious adverse events (SAE)**

866 **7.2.1 Definition of SAE**

A SAE is any medical experience regardless of its relationship to the investigational device or study devices that occurs during subject enrollment in this trial that results in any of the following:

- 870 or need to be hospitalized or prolonged hospitalization;
- 871 or significant disability/incapacity;
- 872 or death of the study subject;
- 873 cs necessitates an intervention to prevent a permanent impairment of a body
 874 function or permanent damage to a body structure
- 875 or causing congenital anomalies/birth defects.
- 876
- 877 **7.2.2 SAE reporting**

878 All SAEs will be recorded in the table of CRF. The details of the SAEs, 879 including starting time, ending time, duration, treatment, outcome, and the 880 relationship with intervention will be recorded as well. Frequency of SAEs will 881 be summarized according to the assignments. All recorded AEs/SAEs will be 882 reported to the investigator. SAEs that result in death or life-threatening stroke 883 will be reported to DSMB/EC within 14 days after the investigator is informed 884 for the first time. In the current trial, SAEs mainly refer disabling stroke, 885 symptomatic intracranial hemorrhage or death within 1 year after enrollment 886 and all-cause death within a follow-up 3 years. For safety analysis, an 887 independent summary will list SAEs related to intervention in PTAS group.

888

889 7.2.3 Management and follow-up of AEs/SAEs

890 Investigators should take appropriate treatment for AEs to ensure the safety 891 of patients and track all AEs/SAEs until they are properly resolved, or the 892 condition is stable. Additional medical procedures and/or referral to a medical specialist may be required to confirm whether the patients are qualified tocontinue to participate in the study.

896 8. DATA MANAGEMENT

897 8.1 Study Data Collection

Site coordinator records data by filling out the paper-based CRF for each case. The sponsor (Beijing Xuanwu Hospital) provides CRFs to each site. Site investigator is responsible for that all CRFs are completed, reviewed, and approved. Also, site investigator will sign on CRFs and confirm that clinical, imaging and laboratory data entered into the CRFs are true.

Patient ID in CRFs should be recorded in an anonymous form, which are only
identified by the patient ID number and Chinese phonetic alphabets (pinyin)
initials. CRFs should be filled in with a black ballpen based on the original
document. Fill in "not done" for missing data; fill in "not applicable" if not
applicable; fill in "unknown" for unknown data.

908 If the data entered into CRFs needs to be revised, cross out the error with a 909 single line so that it can still be seen clearly, and then fill in the correct data 910 next to it. The revisions should be approved and signed by the site 911 investigator. If necessary, the reason for the revisions should be indicated. 912 Site investigator will review the integrity and accuracy of the CRFs and make 913 further corrections and amendments if necessary. When the trial is finished, 914 site investigator will send the CRFs to Tigermed Data Management Co., Ltd; 915 (https://tigermedgrp.com) for data entry.

916 The data in the paper-based CRFs will be entered into the database by 917 Tigermed Data Management Co., Ltd, with its completeness and accuracy 918 reviewed. The missing data and questioned data are reported in the data 919 query form, which will be sent back to the site investigator for further 920 verification. Site investigator will send back in the resolved guery form with 921 signature and date of signing. Tigermed Data Management shall be 922 responsible for entering the resolved results into the database. After the final 923 confirmation is completed and all queries are resolved, the database is 924 updated and locked. Data is transferred from the database directly to the data 925 file (SAS data set) for statistical analysis. The data can be changed after 926 database is unlocked upon reasonable request.

927

928 8.2 Data Processing and Quality Control

929 The data entry is performed by the staff trained by Tigermed Data 930 Management Co., Ltd. All the input data should go through verification and 931 range check. The staff will be notified of a possible error, depending on the 932 data validation. The staff will not move on unless the error is resolved.

All CRFs will be subject to preliminary inspection for data missing,
 inconsistency and deviation. Data inconsistency will be completed by
 electronic tracking and resolved by site coordinators and investigators.

937 Each data input will receive regular cross-check within forms. Site
938 coordinators will be informed in case of errors identified. Corrections to the
939 data in CRFs will be made by the site coordinators, and approved by the site
940 investigators.

941

942 The data editing will continue when all data is cleaned. The site coordinators 943 will supervise the verification of on-site source documents. If further data 944 related to the source file is found during the site visit, additional queries will be 945 generated and processed by the site coordinators.

946

947 **8.3 Data storage**

The investigator will document adequate records during the conduct of the
study. Trial data including patient files, CRFs, ICFs, original copies of results,
and imaging outcome, will be kept on files by the investigator for a period of
10 years or more.

952

954 9. STATISTICAL ANALYSIS

955 9.1 Analysis data set

Full Analysis Set (FAS): all the subjects who are randomized into groups will be included, and the subjects who do not meet the eligible criteria and who withdraw immediately after randomization without receiving any interventions will be excluded. According to the intention-to-treat (ITT) principle, all randomized patients will be analyzed according to the treatment group assigned to them at the time of randomization. All presenting analyses will be conducted in the FAS population unless otherwise specified

963 Per-protocol Set (PPS): PPS refers population who are treated according to 964 the study protocol, e.g., fulfilling eligibility criteria, assigned treatment after 965 randomization, medication and follow-up protocol, and completion of the case 966 report form). PPS analysis was conducted on the population who had not 967 crossovers between groups or significant protocol violations. Crossover 968 population from one arm to the other will not impact the ITT analysis. For 969 PTAS group, significant protocol violations include: 1) use of non-Wingspan 970 stents; 2) delayed procedure of PTAS (beyond 5 business days after 971 enrollment; 3) procedure is aborted before lesion is accessed; 4) procedure is 972 aborted due to total occlusion; 5) receive angioplasty only and others. For 973 other details, please refer to the Statistical Analysis Protocol (SAP) in the 974 Appendix.

For other details, please refer to the Statistical Analysis Protocol (SAP) in theAppendix.

977

978 9.2 Analysis close date

979 The analysis close date for each arm is at the completion of 3-year follow-up 980 of the last enrolled patient. The primary outcome is based on the exact 3-year 981 time point for each patient, and event.

982

983 9.3 Sample size calculation

984 For symptomatic severe (70-99%) intracranial atherosclerotic stenosis, 1 year 985 of ipsilateral stroke risk in medical therapy group WASID study was 18%,³⁶ which was 7.3% in a study by the Wingspan stent therapy.²³ At a significance 986 987 level of 5% on both sides, the absolute difference of 10.7% (relative risk 988 reduction 59%), and a power of 80%, within 12 months of follow-up, a total of 989 302 patients need to be evaluated. Assuming a 20% incidence of loss of 990 follow-up and/or withdrawal, a total of 380 patients, 190 in the stent group and 991 190 in the medical group, are required to be enrolled in this study.

993 **10. STUDY COMMITTEES**

994 **10.1 Executive and Steering Committee**

995 Executive committee is composed of principle and site investigators from the 996 participating centers, which is responsible for making decisions about the 997 direction and strategy of the trial. During the trial period, this committee fulfills 998 the coordination, implementation, organize regular meeting, and report 999 progress. Also, it is required to review main trial publications, analysis plan 1000 and publication policy, and consider recommendations of DSMB.

1001

1002 **10.2 Ethics Committee**

The trial should first obtain the written approval from the Ethics committee of Xuanwu Hospital, Capital Medical University, Beijing, China. The trial will not enroll patient until the study protocol is approved by the local ethics committee (EC) in the other sites. In case of any major amendments to the trial protocol, renewed written approval should be obtained from the ethics committee. Updated ICF after amendments will be sent to patients in the active period of the trial. Minor amendments will not be sent to EC.

1010

1011 **10.3 Data and safety Monitoring Board (DSMB)**

An independent DSMB that is composed of neurologist, neurosurgeon, neuroradiologist and biostatistics experts who are not involved in the conduct of the trial. DSMB members should not have any scientific or financial conflicts of interest with the sponsor or investigator. DSMB is responsible for study conduct, progress and efficacy. By reviewing safety data, DSMB will advise executive committee to continue, modify or terminate the trial early.

1018

1019 **10.4 Clinical outcome committee**

1020 Clinical outcome assessment will be sent to an independent Outcome 1021 Committee. The committee composed of experienced neurologists who are 1022 not involved in the study, will be blinded to the treatment assignment. All the 1023 outcome will be adjudicated by the outcome committee, and a consensus will 1024 be reached by a third clinician in case of discrepancies. For details, please 1025 refer to *2.9 Assessments of clinical outcome* in the *2. Supplementary Methods*.

1026

1027 **10.5 Imaging outcome committee:**

1028 An independent imaging core-lab, IsCore Image CoreLab (ICIC, 1029 http://imagecorelabcn.com/), will be established with the aim of facilitating the 1030 central reading by clinicians and integrating medical imaging at the baseline

- 1031 control and each clinical visit. For details, please refer to 2.10 Assessments of
- 1032 *imaging outcome* in the 2. Supplementary Methods.

1035 **11. ETHICAL AND ADMINISTRATIVE CONSIDERATIONS**

1036 **11.1 Regulatory and ethical compliance**

The design, implementation and reporting of this trial will follow the principles
of the Declaration of Helsinki (World Medical Association: Declaration of
Helsinki, Ethical Principles for Medical Research Involving Human Subjects Version 2008).

1041

1042 **11.2 Recruitment and informed consent form**

Eligible patients who voluntarily agree to participate in the trial will be required to sign a written informed consent form (ICF). The ICF will be signed by the patients or his/her legal regal representatives prior to randomization. They will be informed shortly by the investigators when the treatment is assigned after central randomization.

1048

1049 **11.3 Responsibilities of the investigator**

1050 Site investigators will review the eligibility of each candidate patient. If the 1051 patient is qualified and interested in this trial, he/she will be given written ICF 1052 to participate. Site investigators are responsible for explaining the research 1053 background, intervention, protocol, benefits, and risks of participating in the 1054 trial. A signed ICF copy will be kept by the patient as part of the study files. 1055 The patient is fully entitled to quit at any circumstance.

1056

1057 **11.4 Public disclosure and publication policy**

1058 As the sponsor of the study, Xuanwu Hospital aims to publicize the primary 1059 and secondary outcome results in a high-impact scientific journal. Database 1060 of this trial will be locked within 3 months when the last enrolled patient 1061 finished the scheduled 3-year follow-up and all the data of the enrolled 1062 patients is completed. A manuscript will be submitted for potential publication 1063 in a scientific journal within 3 months after database lock. The manuscript will 1064 be shared with the financial sponsor(s) 3 months before submission, but the 1065 financial sponsor(s) have no influence on its contents. Anonymous data can 1066 be provided by principal investigators upon reasonable request.

1067

12. REFERENCES 1069 1070 1071 1. Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge 1072 burden, significant workload, and a national priority. Stroke 1073 2011;42(12):3651-4. DOI: 10.1161/STROKEAHA.111.635755. 1074 2. Kim AS, Johnston SC. Global variation in the relative burden of stroke and 1075 ischemic heart disease. Circulation 2011;124(3):314-23. DOI: 1076 10.1161/CIRCULATIONAHA.111.018820. 1077 3. Ferri CP. Schoenborn C. Kalra L. et al. Prevalence of stroke and related 1078 burden among older people living in Latin America, India and China. J Neurol 1079 Neurosurg Psychiatry 2011;82(10):1074-82. DOI: 10.1136/jnnp.2010.234153. 1080 4. Wong KS, Li H. Long-term mortality and recurrent stroke risk among Chinese 1081 stroke patients with predominant intracranial atherosclerosis. Stroke 1082 2003;34(10):2361-6. DOI: 10.1161/01.STR.0000089017.90037.7A. 1083 5. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial 1084 occlusive disease: a large worldwide burden but a relatively neglected frontier. 1085 Stroke 2008;39(8):2396-9. DOI: 10.1161/STROKEAHA.107.505776. 1086 6. Arenillas JF. Intracranial atherosclerosis: current concepts. Stroke 2011;42(1 1087 Suppl):S20-3. DOI: 10.1161/STROKEAHA.110.597278. 1088 7. Wong LK. Global burden of intracranial atherosclerosis. Int J Stroke 1089 2006;1(3):158-9. DOI: 10.1111/j.1747-4949.2006.00045.x. 1090 8. Marks MP, Wojak JC, Al-Ali F, et al. Angioplasty for symptomatic intracranial 1091 stenosis: clinical outcome. Stroke 2006;37(4):1016-20. DOI: 1092 10.1161/01.STR.0000206142.03677.c2. 1093 9. Higashida RT, Meyers PM. Intracranial angioplasty and stenting for cerebral 1094 atherosclerosis: new treatments for stroke are needed! Neuroradiology 1095 2006;48(6):367-72. DOI: 10.1007/s00234-006-0071-6. 1096 10. Abou-Chebl A, Bashir Q, Yadav JS. Drug-eluting stents for the treatment of 1097 intracranial atherosclerosis: initial experience and midterm angiographic 1098 follow-up. Stroke 2005;36(12):e165-8. DOI: 1099 10.1161/01.STR.0000190893.74268.fd. 1100 11. Investigators SS. Stenting of Symptomatic Atherosclerotic Lesions in the 1101 Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 1102 2004;35(6):1388-92. DOI: 10.1161/01.STR.0000128708.86762.d6.

1103	12.	Gomez CR, Misra VK, Campbell MS, Soto RD. Elective stenting of
1104		symptomatic middle cerebral artery stenosis. AJNR Am J Neuroradiol
1105		2000;21(5):971-3. (<u>https://www.ncbi.nlm.nih.gov/pubmed/10815680</u>).
1106	13.	Fiorella D, Levy EI, Turk AS, et al. US multicenter experience with the
1107		wingspan stent system for the treatment of intracranial atheromatous disease:
1108		periprocedural results. Stroke 2007;38(3):881-7. DOI:
1109		10.1161/01.STR.0000257963.65728.e8.
1110	14.	Bose A, Hartmann M, Henkes H, et al. A novel, self-expanding, nitinol stent in
1111		medically refractory intracranial atherosclerotic stenoses: the Wingspan study.
1112		Stroke 2007;38(5):1531-7. DOI: 10.1161/STROKEAHA.106.477711.
1113	15.	Zaidat OO, Klucznik R, Alexander MJ, et al. The NIH registry on use of the
1114		Wingspan stent for symptomatic 70-99% intracranial arterial stenosis.
1115		Neurology 2008;70(17):1518-24. DOI: 10.1212/01.wnl.0000306308.08229.a3.
1116	16.	Kurre W, Berkefeld J, Brassel F, et al. In-hospital complication rates after
1117		stent treatment of 388 symptomatic intracranial stenoses: results from the
1118		INTRASTENT multicentric registry. Stroke 2010;41(3):494-8. DOI:
1119		10.1161/STROKEAHA.109.568063.
1120	17.	Nguyen TN, Zaidat OO, Gupta R, et al. Balloon angioplasty for intracranial
1121		atherosclerotic disease: periprocedural risks and short-term outcomes in a
1122		multicenter study. Stroke 2011;42(1):107-11. DOI:
1123		10.1161/STROKEAHA.110.583245.
1124	18.	Chimowitz MI, Lynn MJ, Turan TN, et al. Design of the stenting and
1125		aggressive medical management for preventing recurrent stroke in
1126		intracranial stenosis trial. J Stroke Cerebrovasc Dis 2011;20(4):357-68. DOI:
1127		10.1016/j.jstrokecerebrovasdis.2011.05.001.
1128	19.	Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive
1129		medical therapy for intracranial arterial stenosis. N Engl J Med
1130		2011;365(11):993-1003. DOI: 10.1056/NEJMoa1105335.
1131	20.	Alexander MJ. Intracranial stenting for intracranial atherosclerotic disease:
1132		still much to learn. J Neurointerv Surg 2012;4(2):85-6. DOI:
1133		10.1136/neurintsurg-2012-010269.
1134	21.	Nahab F, Lynn MJ, Kasner SE, et al. Risk factors associated with major
1135		cerebrovascular complications after intracranial stenting. Neurology
1136		2009;72(23):2014-9. DOI: 10.1212/01.wnl.0b013e3181a1863c.

1137	22.	Chaturvedi S, Dumont AS. The learning curve for neuroendovascular
1138		procedures: how important is it? Neurology 2009;72(23):1974-5. DOI:
1139		10.1212/WNL.0b013e3181a92c6f.
1140	23.	Jiang WJ, Yu W, Du B, Gao F, Cui LY. Outcome of patients with >/=70%
1141		symptomatic intracranial stenosis after Wingspan stenting. Stroke
1142		2011;42(7):1971-5. DOI: 10.1161/STROKEAHA.110.595926.
1143	24.	Jiang WJ, Cheng-Ching E, Abou-Chebl A, et al. Multicenter analysis of
1144		stenting in symptomatic intracranial atherosclerosis. Neurosurgery
1145		2012;70(1):25-30; discussion 31. DOI: 10.1227/NEU.0b013e31822d274d.
1146	25.	Zhang L, Huang Q, Zhang Y, et al. A single-center study of Wingspan stents
1147		for symptomatic atherosclerotic stenosis of the middle cerebral artery. J Clin
1148		Neurosci 2013;20(3):362-6. DOI: 10.1016/j.jocn.2012.03.033.
1149	26.	Zhang L, Huang Q, Zhang Y, et al. Wingspan stents for the treatment of
1150		symptomatic atherosclerotic stenosis in small intracranial vessels: safety and
1151		efficacy evaluation. AJNR Am J Neuroradiol 2012;33(2):343-7. DOI:
1152		10.3174/ajnr.A2772.
1153	27.	Levy EI, Chaturvedi S. Perforator stroke following intracranial stenting: a
1154		sacrifice for the greater good? Neurology 2006;66(12):1803-4. DOI:
1155		10.1212/01.wnl.0000227198.02597.15.
1156	28.	Liebeskind DS, Cotsonis GA, Saver JL, et al. Collaterals dramatically alter
1157		stroke risk in intracranial atherosclerosis. Ann Neurol 2011;69(6):963-74. DOI:
1158		10.1002/ana.22354.
1159	29.	Turan TN, Maidan L, Cotsonis G, et al. Failure of antithrombotic therapy and
1160		risk of stroke in patients with symptomatic intracranial stenosis. Stroke
1161		2009;40(2):505-9. DOI: 10.1161/STROKEAHA.108.528281.
1162	30.	Abou-Chebl A. Intracranial stenting with Wingspan: still awaiting a safe
1163		landing. Stroke 2011;42(7):1809-11. DOI: 10.1161/STROKEAHA.111.620229.
1164	31.	Marks MP. Is there a future for endovascular treatment of intracranial
1165		atherosclerotic disease after Stenting and Aggressive Medical Management
1166		for Preventing Recurrent Stroke and Intracranial Stenosis (SAMMPRIS)?
1167		Stroke 2012;43(2):580-4. DOI: 10.1161/STROKEAHA.111.645507.
1168	32.	Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke
1169		in patients with stroke or transient ischemic attack: a guideline for healthcare
1170		professionals from the american heart association/american stroke
1171		association. Stroke 2011;42(1):227-76. DOI:
1172		10.1161/STR.0b013e3181f7d043.

1173	33.	Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI. A standardized
1174		method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol
1175		2000;21(4):643-6. (<u>https://www.ncbi.nlm.nih.gov/pubmed/10782772</u>).
1176	34.	Mori T, Fukuoka M, Kazita K, Mori K. Follow-up study after intracranial
1177		percutaneous transluminal cerebral balloon angioplasty. AJNR Am J
1178		Neuroradiol 1998;19(8):1525-33.
1179		(https://www.ncbi.nlm.nih.gov/pubmed/9763389).
1180	35.	Higashida RT, Furlan AJ, Roberts H, et al. Trial design and reporting
1181		standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
1182		Stroke 2003;34(8):e109-37. DOI: 10.1161/01.STR.0000082721.62796.09.
1183	36.	Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and
1184		aspirin for symptomatic intracranial arterial stenosis. N Engl J Med
1185		2005;352(13):1305-16. DOI: 10.1056/NEJMoa043033.
1186		

1188 **13. APPENDIX**

1189

1190 **13.1 Barthel Index (BI)**

1191 The Barthel scale is an ordinal scale used to measure performance in 1192 activities of daily living (ADL). Each performance item is rated on this scale 1193 with a given number of points assigned to each level or ranking. It uses ten 1194 variables describing ADL and mobility. A higher number is associated with a 1195 greater likelihood of being able to live at home with a degree of independence 1196 following discharge from hospital.

Category	Scale definition	
Feeding	 0 = unable 5 = needs help cutting, spreading butter, etc., or requires modified diet 10 = independent 	
Bathing	0 = dependent 5 = independent (or in shower)	
Grooming	 0 = needs to help with personal care 5 = independent face/hair/teeth/shaving (implements provided) 	
Dressing	0 = dependent 5 = needs help but can do about half unaided 10 = independent (including buttons, zips, laces, etc.)	
Bowels	0 = incontinent (or needs to be given enemas) 5 = occasional accident 10 = continent	
Bladder	0 = incontinent, or catheterized and unable to manage alone 5 = occasional accident 10 = continent	
Toilet use	0 = dependent 5 = needs some help, but can do something alone 10 = independent (on and off, dressing, wiping)	
Transfers (bed to	0 = unable, no sitting balance	

chair and back)	 5 = major help (one or two people, physical), can sit 10 = minor help (verbal or physical) 15 = independent
Mobility (on level surfaces)	 0 = immobile or < 50 yards 5 = wheelchair independent, including corners, > 50 yards 10 = walks with help of one person (verbal or physical) > 50 yards 15 = independent (but may use any aid; for example, stick) > 50 yards
Stairs	0 = unable 5 = needs help (verbal, physical, carrying aid) 10 = independent

1199

1201 **13.2 Modified Rankin Scale (mRS)**

1202

1203 The modified Rankin Scale is a commonly used scale for measuring the 1204 degree of disability or dependence in the daily activities of people who have 1205 suffered a stroke or other causes of neurological disability. The addition of 1206 grade 6 indicates dead.

1207

Grade	Disability	Descriptions
0	No symptoms	No symptoms
1	No significant disability	Able to carry out all usual activities, despite some symptoms.
2	Slight disability	Able to look after own affairs without assistance, but unable to carry out all previous activities.
3	Moderate disability	Requires some help, but able to walk unassisted.
4	Moderately severe disability	Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
5	Severe disability	Requires constant nursing care and attention, bedridden, incontinent.
6	Dead	Dead

1208

1210 **13.3 NIH Stroke Scale**

1211

1212 The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) 1213 is a tool used by healthcare providers to objectively quantify the impairment 1214 caused by a stroke. The NIHSS is composed of 11 items, each of which 1215 scores a specific ability between a 0 and 4. For each item, a score of 0 1216 typically indicates normal function in that specific ability, while a higher score 1217 is indicative of some level of impairment. The individual scores from each item 1218 are summed in order to calculate a patient's total NIHSS score. The maximum 1219 possible score is 42, with the minimum score being a 0.

Instructions	Scale definition
1a. Level of consciousness: The investigator must choose a response if a full evaluation is prevented by such obstacles as an endotracheal tube, language barrier, orotracheal trauma/bandages. A 3 is scored only if the patient makes no movement (other than reflexive posturing) in response to noxious stimulation.	 0 = Alert; keenly responsive. 1 = Not alert; but arousable by minor stimulation to obey, answer, or respond. 2 = Not alert; requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (not stereotyped). 3 = Responds only with reflex motor or autonomic effects or totally unresponsive, flaccid, and areflexic.
1b. LOC Questions: The patient is asked the month and his/her age. The answer must be correct - there is no partial credit for being close. Aphasic and stuporous patients who do not comprehend the questions will score 2. Patients unable to speak because of endotracheal intubation, orotracheal trauma, severe dysarthria from any cause, language barrier, or any other problem not secondary to aphasia are given a 1. It is important that only the initial answer be graded and that the examiner not "help" the patient with verbal or non-verbal	 0 = Answers both correctly. 1 = Answers one correctly. 2 = Answers both incorrectly.

cues.	
1c. LOC Commands: The patient is asked to open and close the eyes and then to grip and release the non-paretic hand. Substitute another one step command if the hands cannot be used. Credit is given if an unequivocal attempt is made but not completed due to weakness. If the patient does not respond to command, the task should be demonstrated to him or her (pantomime), and the result scored (i.e., follows none, one or two commands). Patients with trauma, amputation, or other physical impediments should be given suitable one-step commands. Only the first attempt is scored.	 0 = Performs both tasks correctly. 1 = Performs one task correctly. 2 = Performs neither task correctly.
2. Best gaze: Only horizontal eye movements will be tested. Voluntary or reflexive (oculocephalic) eye movements will be scored, but caloric testing is not done. If the patient has a conjugate deviation of the eyes that can be overcome by voluntary or reflexive activity, the score will be 1. If a patient has an isolated peripheral nerve paresis (CN III, IV or VI), score a 1. Gaze is testable in all aphasic patients. Patients with ocular trauma, bandages, pre- existing blindness, or other disorder of visual acuity or fields should be tested with reflexive movements, and a choice made by the investigator. Establishing eye contact and then moving about the patient from side to side will occasionally clarify the presence of a partial gaze palsy.	 0 = Normal. 1 = Partial gaze palsy; gaze is abnormal in one or both eyes, but forced deviation or total gaze paresis is not present. 2 = Forced deviation, or total gaze paresis not overcome by the oculocephalic maneuver.

3. Visual fields: Visual fields (upper and lower quadrants) are tested by confrontation, using finger counting or visual threat, as appropriate. Patients may be encouraged, but if they look at the side of the moving fingers appropriately, this can be scored as normal. If there is unilateral blindness or enucleation, visual fields in the remaining eye are scored. Score 1 only if a clear- cut asymmetry, including quadrantanopia, is found. If patient is blind from any cause, score 3. Double simultaneous stimulation is performed at this point. If there is extinction, patient receives a 1, and the results are used to respond to item 11.	 0 = No visual loss. 1 = Partial hemianopia. 2 = Complete hemianopia. 3 = Bilateral hemianopia (blind including cortical blindness).
4. Facial palsy: Ask – or use pantomime to encourage – the patient to show teeth or raise eyebrows and close eyes. Score symmetry of grimace in response to noxious stimuli in the poorly responsive or non-comprehending patient. If facial trauma/bandages, orotracheal tube, tape or other physical barriers obscure the face, these should be removed to the extent possible.	 0 = Normal symmetrical movements. 1 = Minor paralysis (flattened nasolabial fold, asymmetry on smiling). 2 = Partial paralysis (total or near-total paralysis of lower face). 3 = Complete paralysis of one or both sides (absence of facial movement in the upper and lower face).
5. Arm motor: The limb is placed in the appropriate position: extend the arms (palms down) 90 degrees (if sitting) or 45 degrees (if supine). Drift is scored if the arm falls before 10 seconds. The aphasic patient is encouraged using urgency in the voice and pantomime, but not	 0 = No drift; limb holds 90 (or 45) degrees for full 10 seconds. 1 = Drift; limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed or other support. 2 = Some effort against gravity; limb cannot get to or maintain (if cued) 90 (or 45)

noxious stimulation. Each limb is tested in turn, beginning with the non-paretic arm. Only in the case of amputation or joint fusion at the shoulder, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice.	 degrees, drifts down to bed, but has some effort against gravity. 3 = No effort against gravity; limb falls. 4 = No movement. UN = Amputation or joint fusion, explain: 5a. Left Arm 5b. Right Arm
6. Leg motor: The limb is placed in the appropriate position: hold the leg at 30 degrees (always tested supine). Drift is scored if the leg falls before 5 seconds. The aphasic patient is encouraged using urgency in the voice and pantomime, but not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic leg. Only in the case of amputation or joint fusion at the hip, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice.	 0 = No drift; leg holds 30-degree position for full 5 seconds. 1 = Drift; leg falls by the end of the 5- second period but does not hit bed. 2 = Some effort against gravity; leg falls to bed by 5 seconds, but has some effort against gravity. 3 = No effort against gravity; leg falls to bed immediately. 4 = No movement. UN = Amputation or joint fusion, explain:
7. Limb ataxia: This item is aimed at finding evidence of a unilateral cerebellar lesion. Test with eyes open. In case of visual defect, ensure testing is done in intact visual field. The finger-nose-finger and heel-shin tests are performed on both sides, and ataxia is scored only if present out of proportion to weakness. Ataxia is absent in the patient who cannot understand or is	0 = Absent. 1 = Present in one limb. 2 = Present in two limbs. UN = Amputation or joint fusion, explain:

paralyzed. Only in the case of amputation or joint fusion, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice. In case of blindness, test by having the patient touch nose from extended arm position.	
8. Sensory: Sensation or grimace to pinprick when tested, or withdrawal from noxious stimulus in the obtunded or aphasic patient. Only sensory loss attributed to stroke is scored as abnormal and the examiner should test as many body areas (arms [not hands], legs, trunk, face) as needed to accurately check for hemisensory loss. A score of 2, "severe or total sensory loss," should only be given when a severe or total loss of sensation can be clearly demonstrated. Stuporous and aphasic patients will, therefore, probably score 1 or 0. The patient with brainstem stroke who has bilateral loss of sensation is scored 2. If the patient does not respond and is quadriplegic, score 2. Patients in a coma (item 1a=3) are automatically given a 2 on this item.	 0 = Normal; no sensory loss. 1 = Mild-to-moderate sensory loss; patient feels pinprick is less sharp or is dull on the affected side; or there is a loss of superficial pain with pinprick, but patient is aware of being touched. 2 = Severe to total sensory loss; patient is not aware of being touched in the face, arm, and leg.
9. Best language: A great deal of information about comprehension will be obtained during the preceding sections of the examination. For this scale item, the patient is asked to describe what is happening in the attached picture, to name the items on the attached naming sheet and to read from the attached list of sentences. Comprehension is judged from	 0 = No aphasia; normal. 1 = Mild-to-moderate aphasia; some obvious loss of fluency or facility of comprehension, without significant limitation on ideas expressed or form of expression. Reduction of speech and/or comprehension, however, makes conversation about provided materials difficult or impossible. For example, in conversation about provided

responses here, as well as to all of the commands in the preceding general neurological exam. If visual loss interferes with the tests, ask the patient to identify objects placed in the hand, repeat, and produce speech. The intubated patient should be asked to write. The patient in a coma (item 1a=3) will automatically score 3 on this item. The examiner must choose a score for the patient with stupor or limited cooperation, but a score of 3 should be used only if the patient is mute and follows no one-step commands.	 materials, examiner can identify picture or naming card content from patient's response. 2 = Severe aphasia; all communication is through fragmentary expression; great need for inference, questioning, and guessing by the listener. Range of information that can be exchanged is limited; listener carries burden of communication. Examiner cannot identify materials provided from patient response. 3 = Mute, global aphasia; no usable speech or auditory comprehension.
10. Dysarthria: If patient is thought to be normal, an adequate sample of speech must be obtained by asking patient to read or repeat words from the attached list. If the patient has severe aphasia, the clarity of articulation of spontaneous speech can be rated. Only if the patient is intubated or has other physical barriers to producing speech, the examiner should record the score as untestable (UN), and clearly write an explanation for this choice. Do not tell the patient why he or she is being tested.	 0 = Normal. 1 = Mild-to-moderate dysarthria; patient slurs at least some words and, at worst, can be understood with some difficulty. 2 = Severe dysarthria; patient's speech is so slurred as to be unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric. UN = Intubated or other physical barrier, explain:
11. Extinction and Inattention (formerly Neglect): Sufficient information to identify neglect may be obtained during the prior testing. If the patient has a severe visual loss preventing visual double simultaneous stimulation, and the cutaneous stimuli are normal, the score is normal. If the patient has aphasia but does appear to attend to both sides, the score is normal. The presence of visual spatial neglect or anosagnosia may also be	 0 = No abnormality. 1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities. 2 = Profound hemi-inattention or extinction to more than one modality; does not recognize own hand or orients to only one side of space.

taken as evider	ken as evide	nce of a	bno	rmality.
Since the abnorr	nce the abnor	mality is a	scor	ed only
if present, the untestable.	•	e item	is	never

1222

1223

1224

1225

1227 **13.4 Mori Classification**

1228

1229 The Mori classification, formulated on the basis of DSA, delineates the length 1230 and geometry of intracranial stenosis as follows:

1231

Туре	Descriptions
A	short (5 mm or less in length) concentric or moderately eccentric lesions less than totally occlusive
В	tubular (5 to 10 mm in length) extremely eccentric or totally occluded lesions, less than 3 months old
С	diffuse lesions (more than 10 mm in length), extremely angulated (>90°) lesions with excessive tortuosity of the proximal segment or totally occluded lesions, 3 months old or older

1232

1234 **13.5 TICI perfusion categories**

1235

1236 The thrombolysis in cerebral infarction (TICI) grading system was described 1237 as a tool for determining the response of thrombolytic therapy for ischemic 1238 stroke. In interventional neuroradiology, it is commonly used for patients post 1239 endovascular revascularization. Like most therapy response grading systems, 1240 it predicts prognosis.

1241

Grade	Descriptions		
0	No Perfusion. No antegrade flow beyond the point of occlusion.		
1	Penetration With Minimal Perfusion. The contrast material passes beyond the area of obstruction but fails to opacify the entire cerebral bed distal to the obstruction for the duration of the angiographic run.		
2	Partial Perfusion. The contrast material passes beyond the obstruction and opacifies the arterial bed distal to the obstruction. However, the rate of entry of contrast into the vessel distal to the obstruction and/or its rate of clearance from the distal bed are perceptibly slower than its entry into and/or clearance from comparable areas not perfused by the previously occluded vessel, e.g., the opposite cerebral artery or the arterial bed proximal to the obstruction.		
	2a	Only partial filling (<2/3) of the entire vascular territory is visualized.	
	2b	Complete filling of all of the expected vascular territory is visualized, but the filling is slower than normal.	
3	Complete Perfusion. Antegrade flow into the bed distal to the obstruction occurs as promptly as into the obstruction and clearance of contrast material from the involved bed is as rapid as from an uninvolved other bed of the same vessel or the opposite cerebral artery.		


1243 **13.6 ASITN/SIR collateral flow grading system**

1244

ASITN/SIR refers to American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR). The grading system scale is determined on DSA, classifying the cerebral collateral status ranging from grade 0 to 4. Grades 0-1, 2 and 3-4 are usually regarded as poor, moderate and good collateral flow.

1250

Grade	Descriptions
0	No collaterals visible to the ischemic site
1	Slow collaterals to the periphery of the ischemic site with persistence of some of the defect
2	Rapid collaterals to the periphery of ischemic site with persistence of some of the defect and to only a portion of the ischemic territory
3	Collaterals with slow but complete angiographic blood flow of the ischemic bed by the late venous phase
4	Complete and rapid collateral blood flow to the vascular bed in the entire ischemic territory by retrograde perfusion





The CASSISS Trial

	1
Full Title	China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): A prospective, multi-center, randomized controlled trial (RCT)
Short Title	The CASSISS Trial
Version	3.0
Date	May 1 st , 2015
	Dr. Liqun Jiao
	Department of Neurosurgery and Interventional Neuroradiology
	Xuanwu Hospital
Principal	China International Neuroscience Institute
investigator	Capital Medical University
	Beijing, China
	Email: liqunjiao@sina.cn
	Telephone: +86-10-83199060
	Dr. Peng Gao
Trial coordinators	Dr. Tao Wang
coordinators	Xuanwu Hospital, Capital Medical University, Beijing, China
	Dr. Daming Wang
	Department of Neurosurgery, Beijing Hospital, Beijing, China, China
	Dr. Huangzhang Shi
	Department of Neurosurgery, the 1st Affiliated Hospital of Harbin Medical University, Harbin, China
Participating	Dr. Tianxiao Li
Participating centers	Department of Intervention, Henan Provincial People's Hospital, Zhengzhou, China
	Dr. Zhenwei Zhao
	Department of Neurosurgery, Tangdu Hospital of Air Force Medical University, Xi'an, China
	Dr. Wei Wu
	Department of Neurology, Qilu Hospital of Shandong University, Ji'nan, China

	<i>Dr. Yiling Cai</i> Department of Neurology, PLA Strategic Support Force Characteristic Medical Center, Beijing, China
	<i>Dr. Weiwen He</i> Department of Neurosurgery, the 2nd affiliated Hospital of Guangzhou Medical University, Guangzhou, China
	<i>Dr. Long Yin</i> Tianjin Huanhu Hospital, Tianjin, China
	<i>Dr. Shengping Huang</i> Guangdong Province Hospital of Traditional Chinese Medicine, Guangzhou, China
Sponsor	Xuanwu Hospital, Capital Medical University
CRO	Tigermed Data Management Co., Ltd
Funding	Ministry of Health, People's Republic of China; Stryker Neurovascular Inc. (Fremont, CA, USA)

1267

1268 **Protocol signature sheet**

Name	Signature	Date
Department of Neurosurgery and Interventional Neuroradiology, China International Neuroscience Institute	Dr. Liqun Jiao	
Xuanwu Hospital, Capital Medical University, Beijing, China		

TABLE OF CONTENTS

1304	6.9.1 Baseline	
1305	6.9.2 Procedure (for PTAS group)	
1306	6.9.3 Discharge	
1307	6.9.4 30-day follow-up	
1308	6.9.5 1-year follow-up	
1309	6.9.6 2-year follow-up	
1310	6.9.7 3-year follow-up	
1311	6.10 CONSENT WITHDRAWAL	
1312	6.11 FOLLOW-UP OF SUBJECTS WITHDRAWN FROM TREATMENT ASSIGNMENT	
1313	6.12 Lost for follow-up	35
1314	6.13 STUDY COMPLETION AND POST-STUDY TREATMENT.	35
1315	6.14 PREMATURE TERMINATION OF THE STUDY	35
1316	6.15 OUTCOME ASSESSMENT	
1317	7. SAFETY MONITORING	
1318	7.1 Adverse events (AE)	
1319	7.2 SERIOUS ADVERSE EVENTS (SAE)	
1320	7.2.1 Definition of SAE	
1321	7.2.2 SAE reporting	
1322	7.2.3 Management and follow-up of AEs/SAEs	
1323	8. DATA MANAGEMENT	
1324	8.1 Study Data Collection	
1325	8.2 DATA PROCESSING AND QUALITY CONTROL	
1326	8.3 DATA STORAGE	
1327	9. STATISTICAL ANALYSIS	40
1328	9.1 ANALYSIS DATA SET	40
1329	9.2 ANALYSIS CLOSE DATE	40
1330	9.3 SAMPLE SIZE CALCULATION.	40
1331	10. STUDY COMMITTEES	41
1332	10.1 EXECUTIVE AND STEERING COMMITTEE	41
1333	10.2 Етніся Сомміттее	41
1334	10.3 Data and safety Monitoring Board (DSMB)	41
1335	10.4 CLINICAL OUTCOME COMMITTEE	41
1336	10.5 Imaging outcome committee:	
1337	11. ETHICAL AND ADMINISTRATIVE CONSIDERATIONS	43

1338	11.1 REGULATORY AND ETHICAL COMPLIANCE	
1339	11.2 RECRUITMENT AND INFORMED CONSENT FORM	
1340	11.3 RESPONSIBILITIES OF THE INVESTIGATOR	
1341	11.4 PUBLIC DISCLOSURE AND PUBLICATION POLICY	
1342	12. REFERENCES	
1343	13. APPENDIX	47
1344	13.1 Barthel Index (BI)	47
1345	13.2 Modified Rankin Scale (MRS)	
1346	13.3 NIH Stroke Scale	
1347	13.4 MORI CLASSIFICATION	57
1348	13.5 TICI PERFUSION CATEGORIES	
1349	13.6 ASITN/SIR COLLATERAL FLOW GRADING SYSTEM	
1350		

1353 **1. LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS**

AE	Adverse Event
AHA	American Heart Association
ALT	Alanine transarninase
APTT	Activated Partial Thromboplastin Time
ASA	American Stroke Association
ASITN/SIR	American Society of Interventional and Therapeutic
	Neuroradiology/Society of Interventional Radiology
	(ASITN/SIR) Collateral Flow Grading System
AST	Aspartate aminotransferase
ATM	Atmosphere
BA	Basilar Artery
BMI	Body Mass Index
BUN	Blood Urea Nitrogen
DSMB	Data Safety and Monitoring Board
DWI	Diffusion-weighted Imaging
ECG	Electrocardiogram
CBF	Cerebral Blood Flow
CBV	Cerebral Blood Volume
Cr	Creatine
CRF	Case Report Form
CRP	C-reactive protein
СТ	Computed Tomography
СТА	Computed Tomography Angiography
CTP	Computed Tomography Perfusion
DSA	Digital Subtraction Angiography
DAPT	Dural Anti-Platelet Therapy
DWI	Diffusion-Weighted Imaging
EC	Ethics Committee, synonymous to Institutional Review

nting
I

Sponsor	The sponsor is the party that commissions the
	organization or performance of the research, for example
	a pharmaceutical company, academic hospital, scientific
	organization or investigator. A party that provides funding
	for a study but does not commission it is not regarded as
	the sponsor, but referred to as a subsidizing party.
тс	Total Cholesterol
TCD	TransCranial Doppler
TIA	Transient Ischemic Attack
TICI	Thrombolysis in Cerebral Infarction
ТТ	Thrombin Time
TTP	Time-to-Peak
USA	United States of America
VA	Vertebral Artery

1357 **2. SUMMARY**

Objectivestherapy alone for preventing the primary outcomes (stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery between 30 days through 1 year in patients with recent TIA or stroke caused by 70% to 99% stenosis of a major intracranial artery).Patient populationPatients with recent TIA or stroke caused by 70% to 99% stenosis of a major intracranial artery.Sample size380 (ratio 1:1)InterventionComplete randomization will be performed with an Interactive Voice Response System (Clinicalsoft Company, Beijing, China). Eligible patients will be randomized with a 1:1 ratio to medical therapy or medical therapy plus PTAS. Superiority is prospectively defined if the stenting arm has a significantly lower stroke or death rate.Study designPrimary outcomes: • Stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 yearMain parametersSecondary outcomes: • Disabling stroke or death after enrollment through 3 years		
Objectiveswith Gateway-Wingspan stent system adds benefit to medical therapy alone for preventing the primary outcomes (stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery between 30 days through 1 year in patients with recent TIA or stroke caused by 70% to 99% stenosis of a major intracranial artery).Patient populationPatients with recent TIA or stroke caused by 70% to 99% stenosis of a major intracranial artery.Sample size380 (ratio 1:1)InterventionComplete randomization will be performed with an Interactive Voice Response System (Clinicalsoft Company, Beijing, China). Eligible patients will be randomized with a 1:1 ratio to medical therapy or medical therapy plus PTAS. Superiority is prospectively defined if the stenting arm has a significantly lower stroke or death rate.Study designprospective, multi-center, open-label, outcome-blinded, randomized controlled study.Main parametersPrimary outcomes: . .Main parametersSecondary outcomes: . .Outcomes .Secondary outcomes: . . .	Title	Severe Stenosis (CASSISS): A prospective, multi-center,
populationstenosis of a major intracranial artery.Sample size380 (ratio 1:1)InterventionComplete randomization will be performed with an Interactive Voice Response System (Clinicalsoft Company, Beijing, China). Eligible patients will be randomized with a 1:1 ratio to medical therapy or medical therapy plus PTAS. Superiority is prospectively defined if the stenting arm has a significantly lower stroke or death rate.Study designprospective, multi-center, open-label, outcome-blinded, randomized controlled study.Main parametersPrimary outcomes: . . . Stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 yearMain parametersSecondary outcomes: . . . Disabling stroke or death after enrollment through 3 years	Objectives	with Gateway-Wingspan stent system adds benefit to medical therapy alone for preventing the primary outcomes (stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery between 30 days through 1 year in patients with recent TIA or stroke caused by
InterventionComplete randomization will be performed with an Interactive Voice Response System (Clinicalsoft Company, Beijing, China). Eligible patients will be randomized with a 1:1 ratio to medical therapy or medical therapy plus PTAS. Superiority is prospectively defined if the stenting arm has a significantly lower stroke or death rate.Study designprospective, multi-center, open-label, outcome-blinded, randomized controlled study.Main parametersPrimary outcomes: .Main parametersStroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 yearMain 		•
InterventionVoice Response System (Clinicalsoft Company, Beijing, China). Eligible patients will be randomized with a 1:1 ratio to medical therapy or medical therapy plus PTAS. Superiority is prospectively defined if the stenting arm has a significantly lower stroke or death rate.Study designprospective, multi-center, open-label, outcome-blinded, randomized controlled study.Primary outcomes: on the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 yearMain parameters / OutcomesSecondary outcomes: o Disabling stroke or death after enrollment through 3 years	Sample size	380 (ratio 1:1)
designrandomized controlled study.Primary outcomes: • Stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 yearMain parameters / OutcomesSecondary outcomes: • Disabling stroke or death after enrollment through 3 years	Intervention	Voice Response System (Clinicalsoft Company, Beijing, China). Eligible patients will be randomized with a 1:1 ratio to medical therapy or medical therapy plus PTAS. Superiority is prospectively defined if the stenting arm has a significantly
 Stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 year / Outcomes Secondary outcomes: Disabling stroke or death after enrollment through 3 years 	-	
 2-year rate of the same-territory stroke; 	parameters	 Stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 year Secondary outcomes: Disabling stroke or death after enrollment through 3 years in both arms;

Follow-up scheduleBaseline, 30-day, 1-year, 2-year, and 3-year•The primary and secondary outcomes including 2-year SIT and 3-year SIT will be compared between the groups using log-rank test by ITT.•For other secondary outcomes and baseline characteristics chi-square or Fisher exact testy will be used for categorical variables, and t-test or Wilcoxon rank test for quantitative variables.•Kaplan-Meier curves will be used to show the incidence o outcomes over time.•All statistical tests will be performed by two-sided test.•A p-value <0.05 is considered statistically significant.•All analyses will be performed with SAS software, version 9.4 (SAS Institute, license: 11202165).		up of 3 years.Death rate in both arms within a follow-up of 3 years.
 SIT and 3-year SIT will be compared between the groups using log-rank test by ITT. For other secondary outcomes and baseline characteristics chi-square or Fisher exact testy will be used for categorical variables, and t-test or Wilcoxon rank test for quantitative variables. Kaplan-Meier curves will be used to show the incidence or outcomes over time. All statistical tests will be performed by two-sided test. A p-value <0.05 is considered statistically significant. All analyses will be performed with SAS software, version 	•	Baseline, 30-day, 1-year, 2-year, and 3-year
 Statistical analysis plan Kaplan-Meier curves will be used to show the incidence or outcomes over time. All statistical tests will be performed by two-sided test. A p-value <0.05 is considered statistically significant. All analyses will be performed with SAS software, version 	analysis	SIT and 3-year SIT will be compared between the groups
 Plan Kaplan-Meier curves will be used to show the incidence of outcomes over time. All statistical tests will be performed by two-sided test. A p-value <0.05 is considered statistically significant. All analyses will be performed with SAS software, version 		characteristics chi-square or Fisher exact testy will be used for categorical variables, and t-test or Wilcoxon rank
 A p-value <0.05 is considered statistically significant. All analyses will be performed with SAS software, version 		•
 All analyses will be performed with SAS software, version 		• All statistical tests will be performed by two-sided test.
· · ·		• A p-value <0.05 is considered statistically significant.

1368 **3. INTRODUCTION AND RATIONALE**

1369

1370 **3.1 Description of the disease**

1371 Stroke is one of the leading causes of death in China and confers a large burden and 1372 effort upon patients and health professionals.¹⁻³ In contrast to Western countries, 1373 intracranial atherosclerotic stenosis (ICAS) is the most common vascular lesion in 1374 patients with cerebrovascular disease, and is an important cause of ischemic stroke 1375 and future recurrent events in China.⁴⁻⁷ Patients with ICAS have long been 1376 considered to be at high risk of recurrent stroke, which led to the development and 1377 wide use of percutaneous transluminal angioplasty and stenting (PTAS).⁸⁻¹²

1378

3.2 Description of the intervention

1380 In 2005, the Wingspan Stent system (Stryker Neurovascular, Fremont, CA, USA) 1381 was approved under a Humanitarian Device Exemption by the US Food and Drug 1382 Administration (FDA), and had been used to reduce the rate of recurrent ischemic events among patients with severe symptomatic ICAS.¹³⁻¹⁷ However, the Stenting 1383 1384 and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial 1385 Stenosis trial (SAMMPRIS trial, ClinicalTrials.gov number, NCT00576693), as the first RCT,¹⁸ demonstrated that aggressive medical management was superior to 1386 1387 PTAS with the Wingspan stent among patients with symptomatic severe ICAS, both 1388 because the risk of early stroke after stenting was high (14.7%) and because the risk 1389 of stroke with aggressive medical therapy alone was lower than expected (5.8%).¹⁹

1390

1391 **3.3 Relevance for clinical practice**

1392 Since the SAMMPRIS trial, concerns have emerged that outcomes seen in a clinical 1393 trial setting may not be reproducible in non-RCT setting because of demonstrated 1394 more optimal surgical outcomes, less complication rates in high-volume centers, and 1395 good patient selection. The technical procedural problem rate, including guidewire-1396 or angioplasty-related hemorrhage, could be minimized as more experienced 1397 operators overcome the learning curve for mastering the safety precautions of Wingspan stenting for ICAS.²⁰⁻²² In the post-SAMMPRIS era, several single or multi-1398 center, registration studies in China,²³⁻²⁶ suggested lower risks of intracranial 1399 stenting for ICAS than those reported for SAMMPRIS.¹⁹ 1400

Second, poor patient selection may increase the peri-operative risks and bias the outcome favoring medical treatment. In the stenting arm of the SAMMPRIS trial, more than 50% (115/224) of patients had a time interval from qualifying event to randomization of less than 7 days.¹⁹ Short interval or early stenting intervention may confer a higher risk of cerebral vascular event, including thromboembolic events, perforator stroke,²⁷ or even hemorrhagic transformation. Also, in the SAMMPRIS trial,
22.8% of recruited patients had perforators stroke only, and those patients may not
benefit from stenting in addition to medical therapy. Ideally, stenting may be
considered for eligible patients based on poor collaterals and medical futility.²⁸

Third, intracranial stenting involves a trade-off between a higher short-term perioperative risk in exchange for a lower long-term risk of stroke. In the SAMMPRIS trial the stenting group, mostly due to periprocedural complication, had more disabling or fatal stroke within 30 days than that in medical group (7.1% vs 1.8%), whereas the stenting group had less disabling or fatal stroke beyond 30 days than that in medical group (2.2% vs 6.2%).¹⁹

The choice for ICAS treatment between medical therapy and stenting remains 1416 1417 incompletely settled, at least for certain high-volume centers and for certain patient 1418 groups in a Chinese population. Furthermore, the recurrent stroke risk in the real 1419 world remains high despite maximal medical therapy.²⁹ Since the SAMMPRIS trial, 1420 an ever-increasing number of PTAS procedures surged beyond guidelines due to 1421 increased demand for ICAS treatment in China. The research community has 1422 maintained interest in tackling this important cause of stroke. Intracranial stenting with Wingspan is still awaiting a safe landing.^{30, 31} 1423

1424

1425 **3.4 Hypothesis and rationale**

1426 It may be hypothesized that the clinical superiority observed in carefully selected 1427 patients in high-volume center who received medical therapy had diminished, 1428 making stenting a more favorable treatment strategy in comparison. As compared to 1429 the design of the SAMMPRIS trial, we thus feel that there is the need for a refined 1430 randomized trial reevaluating the role of stenting for ICAS. In the CASSISS trial, 1431 patients in both treatment groups have been followed up for 3 more years to 1432 establish whether early benefit in the medical group would persist over longer follow-1433 up, or whether the medical group would have a high incidence of late stroke that 1434 would eliminate the early efficacy gap between groups.

1435

1436 **3.5 Objectives**

1437 **3.5.1** Primary objectives

To determine whether PTAS (using the Gateway PTA balloon catheter and Wingspan Stent System, Stryker, Fremont, CA, USA) combined with medical therapy is superior to medical therapy alone for preventing the primary outcome (stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery between 30 days through 1 year in patients with recent TIA or nondisabling stroke caused by 70% to 99% stenosis of a major intracranial artery).

1445 **3.5.2 Secondary objectives**

1446 To compare outcomes between groups in terms of:

• Disabling stroke or death after enrollment through 3 years in both arms;


- **2-year rate of the same-territory stroke**;
- **3**-year rate of the same-territory stroke;
- Any stroke, TIA, or cardiovascular events within a follow-up of 3 years.
- Death rate in both arms within a follow-up of 3 years.

1453 **4. STUDY DESIGN**

1454 This trial is a prospective, multi-center, open-label, outcome-blinded, randomized 1455 control trial that will be conducted in 8 high-volume centers in China Mainland. 1456 Patients who meet inclusion criteria are randomized (1:1) to medical therapy alone or 1457 to PTAS plus medical therapy. This trial aims to enroll 380 cases. This sample size is 1458 large enough to result in acceptable data about safety and efficacy. At each 1459 investigational site, the local treating team will consist of at least a neurologist, a 1460 neurosurgeon, a neuroradiologist, and a research coordinator. The local treating 1461 team conducted enrollment after they reviewed the qualification of each patient. 1462 Patients assigned to the medical group will be discharged without further intervention. 1463 They will be administered aspirin 100 mg plus clopidogrel 75 mg per day for 90 days 1464 (aspirin or clopidogrel alone per day thereafter). Medical therapy will be identical in 1465 both arms and will be similar to the previously-described risk factor management for the SAMMPRIS trial and AHA/ASA guidelines.^{19 32} Patients assigned to the PTAS 1466 1467 group will receive PTAS within 3-5 business days after enrollment. All patients will be 1468 followed-up in outpatient consultation or by telephone contact with the site 1469 investigators at 30-day, 1-year, 2-year, and 3-year marks until the last patient 1470 enrolled finishes 3-year follow-up or if patients die before the close-out visit (see flow 1471 chart).

1472

- 1473 Expected enrollment initiation date: March, 2014
- 1474 Expected enrollment completion date: March, 2017
- 1475 Expected study end date: March, 2020



1478 1479

- Flow Chart
- 1480 *PTAS, percutaneous transluminal angioplasty and stenting

1481

1483**5. STUDY POPULATION**

1484

1485 **5.1 Population**

Patients with recent TIA or stroke caused by 70% to 99% stenosis of a major
intracranial artery. The stenotic degree will be determined on catheter angiogram
using the criteria of the Warfarin-Aspirin Symptomatic Intracranial Disease Study
[WASID].³³

1490

1491 **5.2 Credentialing of the participating centers and center eligibility**

1492 Centers are required to have a team consisting of a neurologist, a neurosurgeon, a 1493 neuroradiologist, and a research coordinator. The randomized trial will not begin until 1494 the clinical results of the participating centers have been certified. All the centers 1495 who are interested in this trial will perform a competitive registration study of 1496 recruiting a consecutive 100 PTAS as a pre-clinical trial within a duration of 8 to 10 1497 months. Certification will be achieved by participating centers, whose clinical results 1498 are audited by means of a validated selection process. Participating centers meet 1499 the following criteria will be included in the randomized trial: 1) at least five cases 1500 were performed by each primary operator during the lead-in phase; 2) annual 1501 volume of intracranial PTAS procedures was more than 30 for the past three years 1502 with a proven track record; and 3) according to the records of the past three years 1503 30-day rate of stroke or death after PTAS in the territory of the qualifying artery was 1504 lower than 15%.

There will be 10 high-volume candidate sites (all tertiary hospitals), involved in a competitive registration study of recruiting a combined total of 100 consecutive patients treated with PTAS:

1508

Table: 10 candidate enrollment sites

#	Sites
1	Xuanwu Hospital, Capital Medical University, Beijing, China
2	The 1st Affiliated Hospital of Harbin Medical University, Harbin, China
3	Henan Provincial People's Hospital, Zhengzhou, China
4	Tangdu Hospital of Air Force Medical University, Xi'an, China
5	Beijing Hospital, Beijing, China
6	Qilu Hospital of Shandong University, Ji'nan, China
7	PLA Strategic support Force Characteristic Medical Center, Beijing,

	China
8	The 2nd affiliated Hospital of Guangzhou Medical University, Guangzhou, China
9	Tianjin Huanhu Hospital, Tianjin, China
10	Guangdong Province Hospital of Traditional Chinese Medicine, Guangzhou, China

1510 **5.3 Inclusion criteria**

1511 1. Eligible patients aged between 30 and 80 years; intracranial arterial stenosis 1512 related to the following non-atherosclerotic factors will be not be considered: 1513 arterial dissection, moya-moya disease; vasculitic disease; herpes zoster, 1514 varicella zoster or other viral vasculopathy; neurosyphilis; any other intracranial 1515 infection; any intracranial stenosis associated with cerebrospinal fluid pleocytosis; 1516 radiation-induced vasculopathy; fibromuscular dysplasia; sickle cell disease; 1517 neurofibromatosis; benign angiopathy of central nervous system; postpartum 1518 angiopathy; suspected vasospastic process, and suspected recanalized embolus;

- Symptomatic intracranial stenosis: presented with transient ischemic stroke (TIA)
 or stroke within the past 12 months attributed to 70%-99% stenosis of a major
 intracranial artery (ICA, MCA [M1], vertebral artery, or basilar artery [BA]);
- 1522 **3.** Degree of stenosis: 70%–99%; stenosis degree must be confirmed by catheter 1523 angiography for enrollment in the trial;
- Remote infarctions on MRI scan, which can be accounted for by the occlusion of the terminal cortical branches or hemodynamic compromise (perforator occlusion excluded). Infarction due to perforators occlusion is defined as basal ganglia or brainstem/thalamus infarction related with M1 or BA stenosis;
- 1528 5. Expected ability to deliver the stent to the lesion;
- 1529 6. All the patients should be performed with stenting beyond a duration of three 1530 weeks from the latest ischemic symptom onset;
- 1531 7. No recent infarctions identified on MRI (indicated as high signals on DWI series)1532 upon enrollment;
- 1533
 8. No massive cerebral infarction (>1/2 MCA territory), intracranial hemorrhage,
 1534 epidural or sub-dural hemorrhage, and intracranial brain tumor on CT or MRI
 1535 scan;
- 1536 9. mRS scale score of <=2;

- 1537 10. Target vessel reference diameter must be measured to be 2.00 mm to 4.50 mm;
 1538 target area of stenosis is <=14 mm in length;
- 1539 11. No childbearing potential or has a negative pregnancy test within the past one
 1540 week prior to study procedure; female patients had normal menses in the last 18
 1541 months;
- 1542 **12**. Patient is willing and able to return for all follow-up visits required by the protocol;
- 154313. Patients understand the purpose and requirements of the study and have signed1544informed consent form.
- 1545

1546 **5.4 Exclusion criteria**

- 15471. Refractory to general anesthesia; not able to be overcome by pre-treatment with1548medical therapy
- 1549 **2**. Any condition that precludes proper angiographic assessment
- 15503. Tandem extracranial or intracranial stenosis (70%–99%) or occlusion that is1551proximal or distal to the target intracranial lesion
- 4. Bilateral intracranial VA stenosis of 70%–99% and uncertainty about which lesion
 is symptomatic (for example, if patient has pon, midbrain, temporal and occipital
 symptoms)
- 15555. Presence of a previously placed intravascular stent or graft in the ipsilateral1556distribution within 30 days
- 15576. Previous treatment of target lesion with a stent, angioplasty, or other mechanical1558device, or plan to perform staged angioplasty followed by stenting of target1559lesion
- 1560 7. Severe vascular tortuosity or anatomy that would preclude the safe introduction1561 of a guiding catheter, guiding sheath or stent placement
- 15628. Plan to perform concomitant angioplasty or stenting of an extracranial vessel1563tandem to an ipsilateral intracranial stenosis
- 1564 9. Presence of intraluminal thrombus proximal to or at the target lesion
- 1565 **10.** Any aneurysm proximal to or distal to intracranial stenotic artery
- 1566 **11.** Intracranial tumors or any intracranial vascular malformations
- 1567 12. Computed tomographic or angiographic evidence of severe calcification at target1568 lesion
- 1569 **13.** Thrombolytic therapy within 24 hours before enrollment

- 1570 14. Evolving stroke or progressive neurologic signs within 24 hours before 1571 enrollment
- 1572 15. Stroke of sufficient size (>5 cm on CT or MRI) to place patient at risk of
 1573 hemorrhagic transformation during the procedure; hemorrhagic transformation of
 1574 an ischemic stroke within the past 15 days
- 157516. Previous spontaneous intracerebral (parenchymal) or other intracranial1576(subarachnoid, subdural, or epidural) hemorrhage within 30 days
- 1577 **17**. Untreated chronic subdural hematoma >5 mm in thickness
- 1578
 18. Other cardiac sources of emboli such as left ventricular aneurysms, intracardiac
 1579
 filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcified
 aortic stenosis, endocarditis, mitral stenosis, atrial septal defect, atrial septal
 aneurysm, left atrial myxoma
- 1582 **19.** Myocardial infarction within previous **30** days
- 1583
 20. Chronic atrial fibrillation; any episode of paroxysmal atrial fibrillation within the
 past six months, or history of paroxysmal atrial fibrillation requiring chronic
 1585
 anticoagulation
- 1586 21. Intolerance or allergic reaction to any of the medical therapy, including aspirin,1587 clopidogrel, heparin, and local or general anesthetics
- 1588 **22.** History of life-threatening allergy to contrast medium. If not life threatening and 1589 can be effectively pre-treated, patient can be enrolled at physicians' discretion
- 1590 23. Recent gastrointestinal bleed that would interfere with antiplatelet therapy
- 1591 24. Active bleeding diathesis or coagulopathy; active peptic ulcer disease, major 1592 systemic hemorrhage within 30 days, active bleeding diathesis, platelets count 1593 <125,000, hematocrit <30, Hgb <10 g/dl, uncorrected INR >1.5, bleeding time >1 1594 minute beyond upper limit normal, or heparin-associated thrombocytopenia that 1595 increases the risk of bleeding, uncontrolled severe hypertension (systolic 1596 BP>180mm hg or diastolic BP>115mm hg), severe liver impairment (AST or 25. 1597 ALT >3 times normal, cirrhosis), creatinine >265.2 mmol/l (unless on dialysis). 1598 Major surgery (including open femoral, aortic, or carotid surgery) within previous 1599 30 days or planned in the next 90 days after enrollment
- 1600 25. Indication for warfarin or heparin beyond enrollment (exceptions allowed for use
 1601 of systemic heparin during stenting procedure or subcutaneous heparin for deep
 1602 venous thrombosis prophylaxis while hospitalized)
- 1603 **26.** Inability to understand and cooperate with study procedures or sign informed 1604 consent

- 1605 27. Severe dementia or psychiatric problems that prevent the patients from following1606 an outpatient program reliably
- 1607 28. Pregnancy or of childbearing potential and unwilling to use contraception for the1608 duration of this study
- 1609 **29.** Actively participating in another drug or device trial that has not completed the 1610 required protocol follow-up period

1612 **6. Methods**

1613

1614 **6.1 Primary outcomes**

• Stroke or death within 30 days after enrollment, or stroke in the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 year

1617 6.2 Secondary outcomes

- 1618 Disabling stroke or death after enrollment through 3 years in both arms;
- 2-year rate of the same-territory stroke;
- **3-year rate of the same-territory stroke**;
- Any stroke, TIA, or cardiovascular events within a follow-up of 3 years.
- Death rate in both arms within a follow-up of 3 years.

1623

1624 **6.3 Definitions of outcomes**

- 16251.Stroke is defined as the rapid loss of brain functions due to disturbance in the1626blood supply to the brain that persists beyond 24 hours. Stroke is diagnosed by1627an independent outcome committee which is composed with experienced1628neurologists. They will collect additional key neuro-images (CT or MR scans) as1629adjunct evidence for outcome classification of ischemic or hemorrhagic stroke;
- 1630
 2. Ischemic stroke is defined as a new focal neurological deficit of sudden onset
 1631
 1631
 1632
 1632
 MRI. Ischemic strokes are further classified by the neurologic adjudicators as
 1633
 being either in or out of the territory of the qualifying artery;
- 16343. Hemorrhagic stroke is defined as parenchymal, sub-arachnoid, or intra-1635ventricular hemorrhage detected by CT or MRI that is associated with new1636neurological signs or symptoms lasting >24 hours or a seizure;
- 1637 **4**. **Death**, any of the following criteria:
- 1638a)Procedure-related deaths, including those related to a complication of the
procedure or treatment for a complication of the procedure.
- 1640b)Death to due to cardiac cause, e.g., myocardial infarction, cardiac1641tamponade, and worsening heart failure
- 1642 c) Death of other cause (e.g., malignancy, trauma and suicide)
- 1643 d) Sudden or unwitnessed death
- 1644 e) Death of unknown cause

- 1645 **5**. Disabling stroke is defined by any of the following:
- 1646a) a modified Rankin score of 3 or more, on a scale of 0 to 6, with higher1647scores indicating greater disability;
- 1648b) an increase in at least one mRS category from an individual's pre-stroke1649baseline
- 1650c)a score on the composite National Institutes of Health Stroke Scale1651(NIHSS) of 7 or more, on a scale of 0 to 42, with higher scores indicating1652more severe deficits;
- 1653 d) an increase in at least 4 NIHSS scales from pre-stroke baseline.
- 16546. Complication rates associated with stenting procedures: refer perforator1655occlusion, guidewire perforation, artery-to-artery embolism, stent thrombosis, or1656reperfusion hemorrhage within 72 hours after PTAS procedures.
- Restenosis rate: if patients have follow-up vascular imaging, the imaging modality will be recorded, in addition to the percent stenosis of the target lesion.
 Re-stenosis is defined as 50% narrowing or greater irrespective of symptoms.
- 16608. TIA: duration of a focal or global neurological deficit <24 h, any variable</th>1661neuroimaging does not demonstrate a new hemorrhage or infarction;
- 1662
 9. Cardiovascular events: refer a class of events that is related to stenting or
 1663 medical therapy, which includes coronary artery diseases (CAD) such as angina
 1664 and myocardial infarction.
- 1665 **10. BI, mRS and NIHSS: please refer the Appendix 13.1, Appendix 13.2 and** 1666 Appendix 13.3.
- 1667 11. Compliance of drug: patients will be contacted at 30-day, 1-year, 2-year and 3 1668 year after enrollment, to gather information regarding the use of anti-platelet
 1669 drugs, changes in prescribed drugs, medical condition and quality of life.
- 1670 **a) very good, 80% 120%;**
- 1671 b) good, 60% 79%;
- 1672 c) fair, 40% 59%;
- 1673 d) poor, < 40%.
- 1674
- 1675
- 1676
- 1677

1678 **6.4 Definitions of other parameters**

- 1679 **6.4.1 Major vascular complications**
- 1680 **1.** Non-neurovascular death: e.g., trauma, suicide, malignancy, or cardiovascular 1681 mortality;
- 16822.Major vascular complication: e.g., aortic dissection, aortic rupture, or annulus1683rupture;
- Access site of access-related vascular injury (dissection, stenosis, perforation, rupture, arteriovenous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, or percutaneous closure device failure) leading to death, life-threatening or major bleeding, or neurological impairment;
- 16884. Distal cerebral embolism from a vascular source requiring surgery or1689endovascular intervention or irreversible neurological damage;
- Any new ipsilateral lower extremity ischemia documented by patient symptoms,
 physical examination, and/or decreased or absent blood flow on lower extremity
 angiogram;
- 1693 **6.** surgery for access site-related nerve injury;
- 1694 **7**. permanent access site-related nerve injury.

1695

- 1696 6.4.2 Minor vascular complications
- Access site of access-related vascular injury (dissection, stenosis, perforation, rupture, arteriovenous fistula, pseudoaneurysm, hematoma, or percutaneous closure device failure) not leading to death, life-threatening or major bleeding, or neurological impairment;
- 1701
 2. Distal cerebral embolism treated with mechanical thrombectomy not resulting in 1702 irreversible neurological damage;
- 1703 3. Any unplanned endovascular stenting or surgical intervention not meeting the1704 criteria for a major vascular complication;
- 4. Vascular repair: e.g., ultrasound-guided compression or injection embolization,
 transcatheter embolization or stent-graft;
- 1707 5. Percutaneous closure device failure.

1709 **6.5 Treatment assignment**

Eligible patients will be enrolled with their baseline data entered into a web-based database system. Patients will be randomized (1:1) to medical therapy alone or medical therapy plus stenting using Wingspan. Randomized outcomes will not be blinded to the patients and their family. When a patient is included for participation, site investigator will be informed. The patients will be excluded from the ITT analysis if they sign the ICF while they are not confirmed eligible with central adjudication.

A summary will be made of patients who are randomized to PTAS group but do not undergo surgery, and the patients who are randomized to medical therapy but receive surgery. Compliance will be assessed by the investigator at each visit using information provided by the care-giver or patients themselves. This information should be recorded in the source document at each visit.

1721

1722 **6.6 Randomization and numbering**

1723 Complete randomization will be performed with an Interactive Voice Response 1724 System (Clinicalsoft Company Limited, Beijing, China; http://ivr.clinicalsoft.cn). 1725 Eligible patients will be randomized with a 1:1 ratio to medical therapy or medical 1726 therapy plus PTAS. Each patient has its unique ID number (center number plus 1727 screening order number) in this trial. This center number will be assigned to each 1728 participating center. Once the patients or their legal representatives sign the 1729 informed consent form (ICF) at each center, they will be assigned with a screening 1730 order number. At each center, the screening order number will be in order of the 1731 patients' enrollment (e.g., 001, 002, 003 and so on).

1732

6.7 Medical group

1734 Patients randomized to medical group will received medical therapy and be 1735 discharged without further intervention.

1736

1737 **6.7.1 Medical therapy**

1738 Medical therapy will be identical in both arms and will be similar to the previously 1739 described risk factor management for the SAMMPRIS trial. In brief, it includes both 1740 aspirin 100 mg plus clopidogrel 75 mg per day for 90 days (aspirin 100 mg or 1741 clopidogrel 75mg alone per day thereafter) and management of risk factors.

The drugs used in the trial are commercially available in China. Several generic aspirin or clopidogrel are available and allowed to be used. Medical therapy regimen,

1744 including DAPT and statin will be purchased by the patients or their family member,

who later received various degrees of reimbursement from the Chinese socialsecurity system.

1747

1748 6.7.2 Management of risk factors

Risk factor control is based on the AHA/ASA guidelines³² and the SAMMPRIS¹⁹ trial 1749 protocol. Medical management of risk factors consists of normalizing low-density 1750 1751 lipoprotein (LDL-C) (statins, target LDL-C <2.58 mmol/l [100 mg/dl]), hypertension 1752 (systolic pressure <140 mmHg and a diastolic pressure <90 mmHg), glucose 1753 disorder (in diabetic patients, hemoglobin A1c [HbA1c] will be checked at enrollment 1754 and during each clinical visit with a target level of <6.5%), and lifestyle modification. 1755 Intensive management of risk factors is applicable to all the included patients (e.g., 1756 hypertension, lipid disorder, diabetes mellitus, overweight, obesity, physical inactivity, 1757 and cigarette smoking).

1758

- 1759 6.7.3 Health education and lifestyle modification
- 17601. Health education and lifestyle modification: quit smoking, moderate-intensity1761physical exercises (at least 3 times per week for 30 min per session).
- 1762 **2.** Obesity: BMI should be maintained below 25 kg/m². Weight reduction is 1763 associated with a lowering in BP and may thereby reduce stroke risk.

1764

1765

1766 **6.8 PTAS group**

- 1767 Patients randomized to PTAS group are to be scheduled for surgery within 3-5
- business days after enrollment. The study protocol requires that the stenting
- 1769 procedure be performed by a qualified operator at each site.

1770

1771 6.8.1 PTAS procedure

1772 Patients randomized to stenting will be placed on DAPT (aspirin, 100 mg daily and 1773 clopidogrel 75 mg daily) for 3-5 consecutive days before the procedure. No loading 1774 dose will be allowed. The study protocol requires that the PTAS procedure is 1775 typically performed under general anesthesia by a credentialed interventionist who 1776 should be the primary operator. The procedure is typically performed via a 1777transfemorally placed 6F-long sheath or guiding catheter. The stenotic lesion is 1778 primarily crossed with a standard 0.014" microcatheter microwire system under high 1779 magnification fluoroscopic roadmap control. Once across the lesion, the 1780 microcatheter is exchanged over a 300-cm, 0.014" microwire for a Gateway balloon 1781 catheter. After angioplasty, the balloon catheter is exchanged for a Wingspan stent 1782 delivery system and the self-expanding Wingspan stent is deployed across the 1783 stenosis. If the residual stenosis after inserting the Wingspan stent is >50%, the 1784 study protocol allows for postdilation with a new balloon catheter. The protocol 1785 required frequent measurements of blood pressure during the procedure and at least 1786 1 measurement every half an hour during the next 24 hours while the patient is 1787 monitored. The patient will be continued on aspirin, 100 mg daily, and clopidogrel, 75 1788 mg daily, for the next 90 days and subsequently on aspirin or clopidogrel alone. Risk 1789 factor control should be applied thereafter.

- 1790
- 1791 **6.8.2 Rescue therapy for PTAS**
- 17921.If the residual stenosis is >50% after the primary Wingspan placement, study1793protocol allows for the postdilation with a new balloon catheter to achieve better1794angioplasty outcome.
- 1795 **2.** If the initial Wingspan stent could not be delivered to the target lesion, the 1796 interventionalist can try to deliver a second Wingspan stent.
- 1797 3. If the second Wingspan stent cannot be delivered to the target lesion, the
 1798 interventionalist has the following options: a) angioplasty alone; b) using non 1799 study stents; c) procedure aborted.
- If an ischemic stroke occurs or an intraluminal thrombus develops during the procedure, the interventionalist or stroke neurologist (if available) should administrate appropriate treatment. This may include intravenous or intraarterial use of thrombolytic therapy, e.g., glycoprotein IIb-IIIa Inhibitor (Tirofiban).
- 1804
 5. If a major dissection, other occlusive complication, or stent misplacement occurs
 1805
 that requires placement of a second Wingspan stent, this may be done as a
 1806
 rescue procedure. In the meantime, neuro ICU will provide reservations to deal
 1807
 with patients with serious complications.
- 1808

1809 **6.9 Follow-up schedule**

1810 Clinical assessment of patients will be conducted in outpatient consultation or by 1811 telephone contact with the site investigators at 30-day, 1-year, 2-year, and 3-year or 1812 if the patients died before the close-out visit. At each follow-up visit, patients will be 1813 examined by study physicians who also manage the patients' vascular risk factors. 1814 Imaging assessment will be achieved by head MRI, CTA, MRA, or DSA at each visit 1815 if possible.

- 1816
- 1817Table: follow-up schedule

	In-hospital		Follow-up (Paper-based CRF)				
	Baseline	Procedure	Discharge	30- day	1- year	2- year	3- year
ICF	×						
In-/Exclusion criteria	×						
Demographics	×						
Medical history	×						
Physical exam	×			×	×	×	×
Neurological status	•		•		•		
NIHSS	×	×	×	×	×	×	×
mRS	×	×	×	×	×	×	×
Barthel Index	×	×	×	×	×	×	×
Lab test	×				×	×	×
Neuro-imaging	•		•		•		
CT/MRI (DWI)	×				×	×	×
TCD/CTA/MRA	×				×	×	×
CTP/PWI	×	×			×	×	X
DSA	×	×			×	×	×
Medication	×			×	×	×	×
AE/SAE		×	×	×	×	×	×

1819

- 1820 **6.9.1 Baseline**
- 1821 At baseline, the following parameters should be documented:
- 1822 I. Date of ICF
- 1823 II. Demographics

1824 III. Medical history

- a. Present history
- 1826

1827

1829

1100011111010

- D.
- b. Previous history, e.g., hypertension, diabetes, lipid disorder, coronary and peripheral artery diseases, smoking and alcohol abuse, etc.

1828 IV. Clinical status

- a. Physical examination
- 1830b. Vital signs: blood pressure, pulse rate, respiratory rate and body1831temperature
- 1832 c. ECG
- 1833 d. BMI
- 1834 V. Neurological status
- 1835 a. NIHSS
- 1836 b. mRS

1837	c. Barthel Index
1838	VI. Lab test
1839	a. Routine blood test
1840	b. Liver function: e.g., ALT, AST, etc.
1841	c. Renal function: e.g., Cr, BUN, etc.
1842	d. Renal damage: proteinuria (according to site's preference and facilities)
1843	e. FBG and HbA1c
1844	f. Lipid level: LDL, HDL and TC
1845	g. Blood coagulation test: APTT, PT, TT, FIB, INR, etc.
1846	h. Inflammation markers: CRP
1847	i. Pregnancy test
1848	VII. Neuro-imaging
1849	a. Cranial CT/MR (DWI)
1850	b. TCD/CTA/MRA
1851	c. CTP/PWI parameters: CBF, CBV, MTT and TTP
1852	d. DSA
1853	
1854	6.9.2 Procedure (for PTAS group)
1855	During the procedure, the following parameters should be documented:
1856	I. Date of the procedure
1857	a. delayed procedure: beyond 5 business day after enrollment
1858	b. procedure on time: within 5 business day after enrollment
1859	II. Operator of the procedure
1860	III. Anesthesia: general or local
1861	IV. Morphological characteristics of the lesion on DSA
1862	a. side: right or left
1863	b. size: diameter and length (mm)
1864	c. location: M1, BA, ICA or VA
1865	d. stenotic degree (%) determined using the WASID criterion ³³
1866	e. Mori classification: type A, B or C ³⁴ (Appendix 13.4)

1867		f. TICI perfusion categories ³⁵ (Appendix 13.5)
1868		g. ASITN/SIR collateral flow grading system ³⁵ (Appendix 13.6)
1869	V.	Type of procedures
1870		a. angioplasty plus stent placement
1871		b. angioplasty alone
1872		c. none
1873	VI.	Angioplasty balloon
1874		a. size: diameter and length (mm)
1875		b. type: Gateway or others
1876		c. number: 1 or more
1877		d. inflation pressure (atm)
1878	VII.	Stent delivered
1879		a. size: diameter and length (mm)
1880		b. type: Wingspan or others
1881		c. number: 1 or more
1882	VIII.	Residual stenosis (%)
1883	IX.	Use of post-dilation:
1884		a. yes or no
1885		b. if yes, type and size of the balloon used
1886		c. inflation pressure (atm)
1887		d. residual stenosis after post-dilation
1888	Х.	Rescue therapy
1889	XI.	Post-PTAS neurological status
1890		a. NIHSS
1891		b. mRS
1892		c. Barthel Index
1893	XII.	AE/SAE
1894		
1895	6.9.3	Discharge
1896	Befor	e discharge, the following parameters should be documented:

1897	I. Neurological status		
1898	a. NIHSS		
1899	b. mRS		
1900	c. Barthel Index		
1901	II. AE/SAE		
1902			
1903	6.9.4 30-day follow-up		
1904	At 30-day follow-up, the following parameters should be documented:		
1905	I. Clinical status		
1906	a. Physical examination		
1907 1908	 b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature 		
1909	c. ECG		
1910	d. BMI		
1911	II. Neurological status		
1912	a. NIHSS		
1913	b. mRS		
1914	c. Barthel Index		
1915	III. Medication		
1916	IV. AE/SAE		
1917			
1918	6.9.5 1-year follow-up		
1919	At 1-year follow-up, the following parameters should be documented:		
1920	I. Clinical status		
1921	a. Physical examination		
1922 1923	 b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature 		
1924	c. ECG		
1925	d. BMI		
1926	II. Neurological status		
1927	a.NIHSS		

1928	b. mRS
1929	c. Barthel Index
1930	III. Lab test
1931	a. Routine blood test
1932	b. Liver function: e.g., ALT, AST, etc.
1933	c. Renal function: e.g., Cr, BUN, etc.
1934	d. Renal damage: proteinuria (according to site's preference and facilities)
1935	e. FBG and HbA1c
1936	f. Lipid level: LDL, HDL and TC
1937	g. Blood coagulation test: APTT, PT, TT, FIB, INR, etc.
1938	h. Inflammation markers: CRP
1939	IV. Neuro-imaging
1940	a. Cranial CT/MR (DWI)
1941	b. TCD/CTA/MRA
1942	c. CTP/PWI parameters: CBF, CBV, MTT and TTP
1943	d. DSA
1944	V. Medication
1945	VI. AE/SAE
1946	
1947	6.9.6 2-year follow-up
1948	At 2-year follow-up, the following parameters should be documented:
1949	I. Clinical status
1950	a. Physical examination
1951 1952	 b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature
1953	c. ECG
1954	d. BMI
1955	II. Neurological status
1956	a. NIHSS
1957	b. mRS

1958	c. Barthel Index
1959	III. Lab test
1960	a. Routine blood test
1961	b. Liver function: e.g., ALT, AST, etc.
1962	c. Renal function: e.g., Cr, BUN, etc.
1963	d. Renal damage: proteinuria (according to site's preference and facilities)
1964	e. FBG and HbA1c
1965	f. Lipid level: LDL, HDL and TC
1966	g. Blood coagulation test: APTT, PT, TT, FIB, INR, etc.
1967	h. Inflammation markers: CRP
1968	IV. Neuro-imaging
1969	a. Cranial CT/MR (DWI)
1970	b. TCD/CTA/MRA
1971	c. CTP/PWI parameters: CBF, CBV, MTT and TTP
1972	d. DSA
1973	V. Medication
1974	VI. AE/SAE
1975	
1975 1976	6.9.7 3-year follow-up
	6.9.7 3-year follow-up The following parameters should be documented:
1976	
1976 1977	The following parameters should be documented:
1976 1977 1978 1979 1980	The following parameters should be documented: I. Clinical status a. Physical examination b. Vital signs: blood pressure, pulse rate, respiratory rate and body
1976 1977 1978 1979 1980 1981	 The following parameters should be documented: I. Clinical status a. Physical examination b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature
1976 1977 1978 1979 1980 1981 1982	 The following parameters should be documented: I. Clinical status a. Physical examination b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature c. ECG
1976 1977 1978 1979 1980 1981 1982 1983	 The following parameters should be documented: I. Clinical status a. Physical examination b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature c. ECG d. BMI
1976 1977 1978 1979 1980 1981 1982 1983 1984	 The following parameters should be documented: I. Clinical status a. Physical examination b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature c. ECG d. BMI I. Neurological status
1976 1977 1978 1979 1980 1981 1982 1983 1984 1985	 The following parameters should be documented: I. Clinical status a. Physical examination b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature c. ECG d. BMI II. Neurological status a. NIHSS
1976 1977 1978 1979 1980 1981 1982 1983 1984	 The following parameters should be documented: I. Clinical status a. Physical examination b. Vital signs: blood pressure, pulse rate, respiratory rate and body temperature c. ECG d. BMI I. Neurological status

1988	III. Lab test
1989	a. Routine blood test
1990	b. Liver function: e.g., ALT, AST, etc.
1991	c. Renal function: e.g., Cr, BUN, etc.
1992	d. Renal damage: proteinuria (according to site's preference and facilities)
1993	e. FBG and HbA1c
1994	f. Lipid level: LDL, HDL and TC
1995	g. Blood coagulation test: APTT, PT, TT, FIB, INR, etc.
1996	h. Inflammation markers: CRP
1997	IV. Neuro-imaging
1998	a. Cranial CT/MR (DWI)
1999	b. TCD/CTA/MRA
2000	c. CTP/PWI parameters: CBF, CBV, MTT and TTP
2001	d. DSA
2002	V. Medication
2003	VI. AE/SAE
0004	

2005 **6.10 Consent withdrawal**

Patients may voluntarily withdraw consent to participate in the study for any reason at any time. Consent withdrawal occurs only when a patient: 1) does not want to participate in the study anymore; 2) or does not want any further visits or assessments; 3) or does not want any further study-related contacts.

When a patient withdraws consent, the investigator is required to determine the primary reason for this decision and record this information. Further attempts to contact the patient are not allowed unless safety efficacy require follow-up. After withdrawal, patients will not be replaced by others and their randomized ID number will not be re-used.

2015

2016 **6.11** Follow-up of subjects withdrawn from treatment assignment

2017 Some cases may withdraw from treatment assignment. Since the statistical analysis 2018 is planned for ITT principle, they will be analyzed in the group that they were 2019 originally allocated to.

6.12 Lost for follow-up

2022 For patients whose status are unclear because they fail to appear for study visits 2023 without stating an intention to withdraw, the investigator should show "due diligence" 2024 by contacting the patient, family or family physician as agreed in ICF and by 2025 documenting in the source documents steps taken to contact the patient, e.g., dates 2026 of telephone calls, registered letters, etc. Lost for follow-up could be accounted by no 2027 reply although try to contact the cases three times or more. A patient should not be 2028 formally considered lost to follow-up until his/her scheduled end of study visit would 2029 have occurred.

2030

2031 **6.13 Study completion and post-study treatment**

At the end of the study visit, the investigator should provide follow-up medical care for all patients who are prematurely withdrawn from the study or refer them for appropriate ongoing care. When the patient has completed all scheduled study assessments, the investigator is required to inform to record the patient completion in the EDC system.

2037

2038 **6.14 Premature termination of the study**

2039 During the trial, AEs or SAEs will be reported to DSMB. The DSMB will monitor 2040 SAEs, major safety events, device and procedure failures and any device-related 2041 adverse events. In the current trial, SAEs mainly refer disabling stroke, symptomatic 2042 intracranial hemorrhage or death within 1 year after enrollment and all-cause death 2043 within a follow-up 3 years. The stopping rules will be developed by DSMB and the 2044 advices of DSMB will be sent to the executive and steering committee of the study. 2045 The Executive and Steering Committee will be responsible for informing the EC 2046 whether the advices are fully implemented or not.

2047

2048 **6.15 Outcome assessment**

This is a multicenter phase IV RCT with open-label treatment and blinded outcome assessment. Outcome assessment will be sent to an independent Outcome Committee. The committee is composed of experienced neurologists who are not involved in the study, will be blinded to the treatment assignment. All the outcome will be adjudicated by the outcome committee, and a consensus will be reached by a third clinician in case of discrepancies.

2056**7. SAFETY MONITORING**

2057 **7.1 Adverse events (AE)**

AE is defined as any unfavorable and unintended sign, symptom or disease that occurs to a subject while enrolled in a clinical investigation, whether or not considered related to the study intervention or device. Medical conditions that exist at study enrollment are not considered an AE unless condition worsens after use of the study intervention or device.

2063

2064 **7.2 Serious adverse events (SAE)**

2065 **7.2.1 Definition of SAE**

A SAE is any medical experience regardless of its relationship to the investigational device or study devices that occurs during subject enrollment in this trial that results in any of the following:

- 2069 s need to be hospitalized or prolonged hospitalization;
- 2070 or persistent or significant disability/incapacity;
- 2071 or death of the study subject;
- 2072 or necessitates an intervention to prevent a permanent impairment of a body 2073 function or permanent damage to a body structure
- 2074 or causing congenital anomalies/birth defects.
- 2075
- 2076 **7.2.2 SAE reporting**

2077 All SAEs will be recorded in the table of CRF. The details of the SAEs, including 2078 starting time, ending time, duration, treatment, outcome, and the relationship with 2079 intervention will be recorded as well. Frequency of SAEs will be summarized 2080 according to the assignments. All recorded AEs/SAEs will be reported to the 2081 investigator. SAEs that result in death or life-threatening stroke will be reported to 2082 DSMB/EC within 14 days after the investigator is informed for the first time. In the 2083 current trial, SAEs mainly refer disabling stroke, symptomatic intracranial 2084 hemorrhage or death within 1 year after enrollment and all-cause death within a 2085 follow-up 3 years. For safety analysis, an independent summary will list SAEs related 2086 to intervention in PTAS group.

2087

2088 7.2.3 Management and follow-up of AEs/SAEs

2089 Investigators should take appropriate treatment for AEs to ensure the safety of 2090 patients and track all AEs/SAEs until they are properly resolved, or the condition is

- 2091 $\,$ stable. Additional medical procedures and/or referral to a medical specialist may be
- required to confirm whether the patients are qualified to continue to participate in thestudy.

2095 8. DATA MANAGEMENT

2096 8.1 Study Data Collection

Site coordinator records data by filling out the paper-based CRFs for each case. The sponsor (Beijing Xuanwu Hospital) provides CRFs to each site. Site investigator is responsible for that all CRFs are completed, reviewed, and approved. Also, site investigator will sign on CRFs and confirm that clinical, imaging and laboratory data entered into the CRFs are true.

Patient ID in CRFs should be recorded in an anonymous form, which are only identified by the patient ID number and Chinese phonetic alphabets (pinyin) initials. CRFs should be filled in with a black ballpen based on the original document. Fill in "not done" for missing data; fill in "not applicable" if not applicable; fill in "unknown" for unknown data.

If the data entered into CRFs needs to be revised, cross out the error with a single line so that it can still be seen clearly, and then fill in the correct data next to it. The revisions should be approved and signed by the site investigator. If necessary, the reason for the revisions should be indicated. Site investigator will review the integrity and accuracy of the CRFs and make further corrections and amendments if necessary. When the trial is finished, site investigator will send the CRFs to Tigermed Data Management Co., Ltd; (https://tigermedgrp.com) for data entry.

2114 The data in the paper-based CRFs will be entered into the database by Tigermed 2115 Data Management Co., Ltd, with its completeness and accuracy reviewed. The 2116 missing data and questioned data are reported in the data query form, which will be 2117 sent back to the site investigator for further verification. Site investigator will send 2118 back in the resolved query form with signature and date of signing. Tigermed Data 2119 Management shall be responsible for entering the resolved results into the database. 2120 After the final confirmation is completed and all queries are resolved, the database is 2121 updated and locked. Data is transferred from the database directly to the data file 2122 (SAS data set) for statistical analysis. The data can be changed after database is 2123 unlocked upon reasonable request.

2124

2125 8.2 Data Processing and Quality Control

The data entry is performed by the staff trained by Tigermed Data Management Co., Ltd. All the input data should go through verification and range check. The staff will be notified of a possible error, depending on the data validation. The staff will not move on unless the error is resolved.

2130 All CRFs will be subject to preliminary inspection for data missing, inconsistency and

2131 deviation. Data inconsistency will be completed by electronic tracking and resolved

2132 by site coordinators and investigators.

Each data input will receive regular cross-check within forms. Site coordinators will be informed in case of errors identified. Corrections to the data in CRFs will be made by the site coordinators, and approved by the site investigators.

2137

The data editing will continue when all data is cleaned. The site coordinators will supervise the verification of on-site source documents. If further data related to the source file is found during the site visit, additional queries will be generated and processed by the site coordinators.

2142

8.3 Data storage

- 2144 The investigator will document adequate records during the conduct of the study.
- 2145 Trial data including patient files, CRFs, ICFs, original copies of results, and imaging
- outcome, will be kept on files by the investigator for a period of 10 years or more.

2147

21499. STATISTICAL ANALYSIS

2150 **9.1 Analysis data set**

Full Analysis Set (FAS): all the subjects who are randomized into groups will be included. Subjects who do not meet the eligible criteria or who withdraw immediately after randomization without receiving any interventions will be excluded. According to the intention-to-treat (ITT) principle, all randomized patients will be analyzed according to the treatment group assigned to them at the time of randomization. All presenting analyses will be conducted in the FAS population unless otherwise specified

2158 Per-protocol Set (PPS): PPS refers population who are treated according to the 2159 study protocol, e.g., fulfilling eligibility criteria, assigned treatment after randomization, 2160 medication and follow-up protocol, and completion of the case report form). PPS 2161 analysis was conducted on the population who had not crossovers between groups 2162 or significant protocol violations. Crossover population from one arm to the other will 2163 not impact the ITT analysis. For PTAS group, significant protocol violations include: 1) 2164 use of non-study stents; 2) delayed procedure of PTAS (beyond 5 business days 2165 after enrollment; 3) procedure is aborted before lesion is accessed; 4) procedure is 2166 aborted due to total occlusion; 5) receive angioplasty only and others.

For other details, please refer to the Statistical Analysis Protocol (SAP) in the Appendix.

2169

2170 9.2 Analysis close date

The analysis close date for each arm is at the completion of 3-year follow-up of the last enrolled patient. The primary outcome is based on the exact 3-year time point for each patient, and event.

2174

2175 **9.3 Sample size calculation**

2176 For symptomatic severe (70-99%) intracranial atherosclerotic stenosis, 1 year of ipsilateral stroke risk in medical therapy group WASID study was 18%,³⁶ which was 2177 7.3% in a study by the Wingspan stent therapy.²³ At a significance level of 5% on 2178 2179 both sides, the absolute difference of 10.7% (relative risk reduction 59%), and a 2180 power of 80%, within 12 months of follow-up, a total of 302 patients need to be 2181 evaluated. Assuming a 20% incidence of loss of follow-up and/or withdrawal, a total 2182 of 380 patients, 190 in the stent group and 190 in the medical group, are required to 2183 be enrolled in this study.

2185**10. STUDY COMMITTEES**

2186 **10.1 Executive and Steering Committee**

Executive committee is composed of principle and site investigators from the participating centers, which is responsible for making decisions about the direction and strategy of the trial. During the trial period, this committee fulfills the coordination, implementation, organize regular meeting, and report progress. Also, it is required to review main trial publications, analysis plan and publication policy, and consider recommendations of DSMB.

2193

2194 **10.2 Ethics Committee**

The trial should first obtain the written approval from the Ethics committee of Xuanwu Hospital, Capital Medical University, Beijing, China. The trial will not enroll patient until the study protocol is approved by the local ethics committee (EC) in the other sites. In case of any major amendments to the trial protocol, renewed written approval should be obtained from the ethics committee. Updated ICF after amendments will be sent to patients in the active period of the trial. Minor amendments will not be sent to EC.

2202

2203 **10.3 Data and safety Monitoring Board (DSMB)**

An independent DSMB that is composed of neurologist, neurosurgeon, neuroradiologist and biostatistics experts who are not involved in the conduct of the trial. DSMB members should not have any scientific or financial conflicts of interest with the sponsor or investigator. DSMB is responsible for study conduct, progress and efficacy. By reviewing safety data, DSMB will advise executive committee to continue, modify or terminate the trial early.

2210

2211 **10.4 Clinical outcome committee**

2212 Clinical outcome assessment will be sent to an independent Outcome Committee. 2213 The committee composed of experienced neurologists who are not involved in the 2214 study, will be blinded to the treatment assignment. All the outcomes will be 2215 adjudicated by the outcome committee, and a consensus will be reached by a third 2216 clinician in case of discrepancies. For details, please refer to *2.9 Assessments of* 2217 *clinical outcome* in the *2. Supplementary Methods*.

2219 **10.5 Imaging outcome committee:**

2220 independent core-lab, CoreLab An imaging IsCore Image (ICIC, 2221 http://imagecorelabcn.com/), will be established with the aim of facilitating the central 2222 reading by clinicians and integrating medical imaging at the baseline control and 2223 each clinical visit. For details, please refer to 2.10 Assessments of imaging outcome 2224 in the 2. Supplementary Methods.

2225

2227 11. ETHICAL AND ADMINISTRATIVE CONSIDERATIONS

2228 **11.1 Regulatory and ethical compliance**

The design, implementation and reporting of this trial will follow the principles of the Declaration of Helsinki (World Medical Association: Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects - Version 2008).

2232

2233 **11.2 Recruitment and informed consent form**

Eligible patients who voluntarily agree to participate in the trial will be required to sign a written informed consent form (ICF). The ICF will be signed by the patients or his/her legal regal representatives prior to randomization. They will be informed shortly by the investigators when the treatment is assigned after central randomization.

2239

11.3 Responsibilities of the investigator

Site investigators will review the eligibility of each candidate patient. If the patient is qualified and interested in this trial, he/she will be given written ICF to participate. Site investigators are responsible for explaining the research background, intervention, protocol, benefits, and risks of participating in the trial. A signed ICF copy will be kept by the patient as part of the study files. The patient is fully entitled to quit at any circumstance.

2247

2248 **11.4 Public disclosure and publication policy**

2249 As the sponsor of the study, Xuanwu Hospital aims to publicize the primary and 2250 secondary outcome results in a high-impact scientific journal. Database of this trial 2251 will be locked within 3 months when the last enrolled patient finished the scheduled 2252 3-year follow-up and all the data of the enrolled patients is completed. A manuscript 2253 will be submitted for potential publication in a scientific journal within 3 months after 2254 database lock. The manuscript will be shared with the financial sponsor(s) 3 months 2255 before submission, but the financial sponsor(s) have no influence on its contents. 2256 Anonymous data can be provided by principal investigators upon reasonable request.

2257

2259 **12. REFERENCES**

2260

2261 1. Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, 2262 significant workload, and a national priority. Stroke. Dec 2011;42(12):3651-4. 2263 doi:10.1161/STROKEAHA.111.635755 2264 2. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic 2265 heart disease. Circulation. Jul 19 2011;124(3):314-23. 2266 doi:10.1161/CIRCULATIONAHA.111.018820 2267 3. Ferri CP, Schoenborn C, Kalra L, et al. Prevalence of stroke and related burden 2268 among older people living in Latin America, India and China. J Neurol Neurosurg 2269 Psychiatry. Oct 2011;82(10):1074-82. doi:10.1136/jnnp.2010.234153 2270 4. Wong KS, Li H. Long-term mortality and recurrent stroke risk among Chinese stroke 2271 patients with predominant intracranial atherosclerosis. Stroke. Oct 2003;34(10):2361-6. 2272 doi:10.1161/01.STR.0000089017.90037.7A 2273 5. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive 2274 disease: a large worldwide burden but a relatively neglected frontier. Stroke. Aug 2275 2008;39(8):2396-9. doi:10.1161/STROKEAHA.107.505776 2276 6. Arenillas JF. Intracranial atherosclerosis: current concepts. Stroke. Jan 2011;42(1 2277 Suppl):S20-3. doi:10.1161/STROKEAHA.110.597278 2278 7. Wong LK. Global burden of intracranial atherosclerosis. Int J Stroke. Aug 2279 2006;1(3):158-9. doi:10.1111/j.1747-4949.2006.00045.x 2280 Marks MP, Wojak JC, Al-Ali F, et al. Angioplasty for symptomatic intracranial stenosis: 8. 2281 clinical outcome. Stroke. Apr 2006;37(4):1016-20. 2282 doi:10.1161/01.STR.0000206142.03677.c2 2283 Higashida RT, Meyers PM. Intracranial angioplasty and stenting for cerebral 9. 2284 atherosclerosis: new treatments for stroke are needed! Neuroradiology. Jun 2285 2006;48(6):367-72. doi:10.1007/s00234-006-0071-6 2286 10. Abou-Chebl A, Bashir Q, Yadav JS. Drug-eluting stents for the treatment of intracranial 2287 atherosclerosis: initial experience and midterm angiographic follow-up. Stroke. Dec 2288 2005;36(12):e165-8. doi:10.1161/01.STR.0000190893.74268.fd 2289 11. Investigators SS. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or 2290 Intracranial Arteries (SSYLVIA): study results. Stroke. Jun 2004;35(6):1388-92. 2291 doi:10.1161/01.STR.0000128708.86762.d6 2292 12. Gomez CR, Misra VK, Campbell MS, Soto RD. Elective stenting of symptomatic 2293 middle cerebral artery stenosis. AJNR Am J Neuroradiol. May 2000;21(5):971-3. 2294 13. Fiorella D, Levy EI, Turk AS, et al. US multicenter experience with the wingspan stent 2295 system for the treatment of intracranial atheromatous disease: periprocedural results. 2296 Stroke. Mar 2007;38(3):881-7. doi:10.1161/01.STR.0000257963.65728.e8 2297 Bose A, Hartmann M, Henkes H, et al. A novel, self-expanding, nitinol stent in 14. 2298 medically refractory intracranial atherosclerotic stenoses: the Wingspan study. Stroke. 2299 May 2007;38(5):1531-7. doi:10.1161/STROKEAHA.106.477711 2300 Zaidat OO, Klucznik R, Alexander MJ, et al, The NIH registry on use of the Wingspan 15. 2301 stent for symptomatic 70-99% intracranial arterial stenosis. *Neurology*. Apr 22 2302 2008;70(17):1518-24. doi:10.1212/01.wnl.0000306308.08229.a3 2303 Kurre W, Berkefeld J, Brassel F, et al. In-hospital complication rates after stent 16. 2304 treatment of 388 symptomatic intracranial stenoses: results from the INTRASTENT 2305 multicentric registry. Stroke. Mar 2010;41(3):494-8. 2306 doi:10.1161/STROKEAHA.109.568063 2307 17. Nguyen TN, Zaidat OO, Gupta R, et al. Balloon angioplasty for intracranial 2308 atherosclerotic disease: periprocedural risks and short-term outcomes in a multicenter 2309 study. Stroke. Jan 2011;42(1):107-11. doi:10.1161/STROKEAHA.110.583245

2310 Chimowitz MI, Lynn MJ, Turan TN, et al. Design of the stenting and aggressive 18. 2311 medical management for preventing recurrent stroke in intracranial stenosis trial. J 2312 Stroke Cerebrovasc Dis. Jul-Aug 2011;20(4):357-68. 2313 doi:10.1016/j.jstrokecerebrovasdis.2011.05.001 2314 19. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical 2315 therapy for intracranial arterial stenosis. N Engl J Med. Sep 15 2011;365(11):993-1003. 2316 doi:10.1056/NEJMoa1105335 2317 20. Alexander MJ. Intracranial stenting for intracranial atherosclerotic disease: still much to 2318 learn. J Neurointerv Surg. Mar 2012;4(2):85-6. doi:10.1136/neurintsurg-2012-010269 2319 21. Nahab F, Lynn MJ, Kasner SE, et al. Risk factors associated with major 2320 cerebrovascular complications after intracranial stenting. Neurology. Jun 9 2321 2009;72(23):2014-9. doi:10.1212/01.wnl.0b013e3181a1863c 2322 22. Chaturvedi S, Dumont AS. The learning curve for neuroendovascular procedures: how 2323 important is it? *Neurology*. Jun 9 2009;72(23):1974-5. 2324 doi:10.1212/WNL.0b013e3181a92c6f 2325 23. Jiang WJ, Yu W, Du B, Gao F, Cui LY. Outcome of patients with >/=70% symptomatic 2326 intracranial stenosis after Wingspan stenting. Stroke. Jul 2011;42(7):1971-5. 2327 doi:10.1161/STROKEAHA.110.595926 2328 24. Jiang WJ, Cheng-Ching E, Abou-Chebl A, et al. Multicenter analysis of stenting in 2329 symptomatic intracranial atherosclerosis. *Neurosurgery*. Jan 2012;70(1):25-30; 2330 discussion 31. doi:10.1227/NEU.0b013e31822d274d 2331 25. Zhang L, Huang Q, Zhang Y, et al. A single-center study of Wingspan stents for 2332 symptomatic atherosclerotic stenosis of the middle cerebral artery. J Clin Neurosci. 2333 Mar 2013;20(3):362-6. doi:10.1016/j.jocn.2012.03.033 2334 Zhang L, Huang Q, Zhang Y, et al. Wingspan stents for the treatment of symptomatic 26. 2335 atherosclerotic stenosis in small intracranial vessels: safety and efficacy evaluation. 2336 AJNR Am J Neuroradiol. Feb 2012;33(2):343-7. doi:10.3174/ajnr.A2772 2337 27. Levy EI, Chaturvedi S. Perforator stroke following intracranial stenting: a sacrifice for 2338 the greater good? Neurology. Jun 27 2006;66(12):1803-4. 2339 doi:10.1212/01.wnl.0000227198.02597.15 2340 Liebeskind DS, Cotsonis GA, Saver JL, et al. Collaterals dramatically alter stroke risk 28. 2341 in intracranial atherosclerosis. Ann Neurol. Jun 2011;69(6):963-74. 2342 doi:10.1002/ana.22354 2343 29. Turan TN, Maidan L, Cotsonis G, et al. Failure of antithrombotic therapy and risk of 2344 stroke in patients with symptomatic intracranial stenosis. Stroke. Feb 2009;40(2):505-9. 2345 doi:10.1161/STROKEAHA.108.528281 2346 30. Abou-Chebl A. Intracranial stenting with Wingspan: still awaiting a safe landing. Stroke. 2347 Jul 2011;42(7):1809-11. doi:10.1161/STROKEAHA.111.620229 2348 31. Marks MP. Is there a future for endovascular treatment of intracranial atherosclerotic 2349 disease after Stenting and Aggressive Medical Management for Preventing Recurrent 2350 Stroke and Intracranial Stenosis (SAMMPRIS)? Stroke. Feb 2012;43(2):580-4. 2351 doi:10.1161/STROKEAHA.111.645507 2352 32. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in 2353 patients with stroke or transient ischemic attack: a guideline for healthcare 2354 professionals from the american heart association/american stroke association. Stroke. 2355 Jan 2011;42(1):227-76. doi:10.1161/STR.0b013e3181f7d043 2356 33. Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI. A standardized method 2357 for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol. Apr 2358 2000;21(4):643-6. 2359 34. Mori T, Fukuoka M, Kazita K, Mori K. Follow-up study after intracranial percutaneous 2360 transluminal cerebral balloon angioplasty. AJNR Am J Neuroradiol. Sep 2361 1998;19(8):1525-33.

- 236235.Higashida RT, Furlan AJ, Roberts H, et al. Trial design and reporting standards for2363intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. Aug23642003;34(8):e109-37. doi:10.1161/01.STR.0000082721.62796.09
- 236536.Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for2366symptomatic intracranial arterial stenosis. N Engl J Med. Mar 31 2005;352(13):1305-236716. doi:10.1056/NEJMoa043033

2370 **13. APPENDIX**

2371

13.1 Barthel Index (BI)

The Barthel scale is an ordinal scale used to measure performance in activities of daily living (ADL). Each performance item is rated on this scale with a given number of points assigned to each level or ranking. It uses ten variables describing ADL and mobility. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital.

Category	Scale definition
Feeding	 0 = unable 5 = needs help cutting, spreading butter, etc., or requires modified diet 10 = independent
Bathing	0 = dependent 5 = independent (or in shower)
Grooming	0 = needs to help with personal care 5 = independent face/hair/teeth/shaving (implements provided)
Dressing	0 = dependent 5 = needs help but can do about half unaided 10 = independent (including buttons, zips, laces, etc.)
Bowels	 0 = incontinent (or needs to be given enemas) 5 = occasional accident 10 = continent
Bladder	 0 = incontinent, or catheterized and unable to manage alone 5 = occasional accident 10 = continent
Toilet use	0 = dependent 5 = needs some help, but can do something alone 10 = independent (on and off, dressing, wiping)

Transfers (bed to chair and back)	 0 = unable, no sitting balance 5 = major help (one or two people, physical), can sit 10 = minor help (verbal or physical) 15 = independent
Mobility (on level surfaces)	 0 = immobile or < 50 yards 5 = wheelchair independent, including corners, > 50 yards 10 = walks with help of one person (verbal or physical) > 50 yards 15 = independent (but may use any aid; for example, stick) > 50 yards
Stairs	0 = unable 5 = needs help (verbal, physical, carrying aid) 10 = independent

2380

2382 **13.2 Modified Rankin Scale (mRS)**

2383

The modified Rankin Scale is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The addition of grade 6 indicates dead.

2387

Grade	Disability	Descriptions	
0	No symptoms	No symptoms	
1	No significant disability	Able to carry out all usual activities, despite some symptoms.	
2	Slight disability	Able to look after own affairs without assistance, but unable to carry out all previous activities.	
3	Moderate disability	Requires some help, but able to walk unassisted.	
4	Moderately severe disability	Unable to attend to own bodily needs without assistance, and unable to walk unassisted.	
5	Severe disability	Requires constant nursing care and attention, bedridden, incontinent.	
6	Dead	Dead	

2388

13.3 NIH Stroke Scale

2391

2392 The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool 2393 used by healthcare providers to objectively quantify the impairment caused by a 2394 stroke. The NIHSS is composed of 11 items, each of which scores a specific ability 2395 between a 0 and 4. For each item, a score of 0 typically indicates normal function in 2396 that specific ability, while a higher score is indicative of some level of impairment. 2397 The individual scores from each item are summed in order to calculate a patient's 2398 total NIHSS score. The maximum possible score is 42, with the minimum score 2399 being a 0.

Instructions	Scale definition
1a. Level of consciousness: The investigator must choose a response if a full evaluation is prevented by such obstacles as an endotracheal tube, language barrier, orotracheal trauma/bandages. A 3 is scored only if the patient makes no movement (other than reflexive posturing) in response to noxious stimulation.	 0 = Alert; keenly responsive. 1 = Not alert; but arousable by minor stimulation to obey, answer, or respond. 2 = Not alert; requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (not stereotyped). 3 = Responds only with reflex motor or autonomic effects or totally unresponsive, flaccid, and areflexic.
1b. LOC Questions: The patient is asked the month and his/her age. The answer must be correct - there is no partial credit for being close. Aphasic and stuporous patients who do not comprehend the questions will score 2. Patients unable to speak because of endotracheal intubation, orotracheal trauma, severe dysarthria from any cause, language barrier, or any other problem not secondary to aphasia are given a 1. It is important that only the initial answer be graded	 0 = Answers both correctly. 1 = Answers one correctly. 2 = Answers both incorrectly.

and that the examiner not "help" the patient with verbal or non-verbal cues.	
1c. LOC Commands: The patient is asked to open and close the eyes and then to grip and release the non-paretic hand. Substitute another one step command if the hands cannot be used. Credit is given if an unequivocal attempt is made but not completed due to weakness. If the patient does not respond to command, the task should be demonstrated to him or her (pantomime), and the result scored (i.e., follows none, one or two commands). Patients with trauma, amputation, or other physical impediments should be given suitable one-step commands. Only the first attempt is scored.	 0 = Performs both tasks correctly. 1 = Performs one task correctly. 2 = Performs neither task correctly.
2. Best gaze: Only horizontal eye movements will be tested. Voluntary or reflexive (oculocephalic) eye movements will be scored, but caloric testing is not done. If the patient has a conjugate deviation of the eyes that can be overcome by voluntary or reflexive activity, the score will be 1. If a patient has an isolated peripheral nerve paresis (CN III, IV or VI), score a 1. Gaze is testable in all aphasic patients. Patients with ocular trauma, bandages, pre- existing blindness, or other disorder of visual acuity or fields should be tested with reflexive movements, and a choice made by the investigator. Establishing eye	 0 = Normal. 1 = Partial gaze palsy; gaze is abnormal in one or both eyes, but forced deviation or total gaze paresis is not present. 2 = Forced deviation, or total gaze paresis not overcome by the oculocephalic maneuver.

contact and then moving about the patient from side to side will occasionally clarify the presence of a partial gaze palsy.	
3. Visual fields: Visual fields (upper and lower quadrants) are tested by confrontation, using finger counting or visual threat, as appropriate. Patients may be encouraged, but if they look at the side of the moving fingers appropriately, this can be scored as normal. If there is unilateral blindness or enucleation, visual fields in the remaining eye are scored. Score 1 only if a clear- cut asymmetry, including quadrantanopia, is found. If patient is blind from any cause, score 3. Double simultaneous stimulation is performed at this point. If there is extinction, patient receives a 1, and the results are used to respond to item 11.	 0 = No visual loss. 1 = Partial hemianopia. 2 = Complete hemianopia. 3 = Bilateral hemianopia (blind including cortical blindness).
4. Facial palsy: Ask – or use pantomime to encourage – the patient to show teeth or raise eyebrows and close eyes. Score symmetry of grimace in response to noxious stimuli in the poorly responsive or non-comprehending patient. If facial trauma/bandages, orotracheal tube, tape or other physical barriers obscure the face, these should be removed to the extent possible.	 0 = Normal symmetrical movements. 1 = Minor paralysis (flattened nasolabial fold, asymmetry on smiling). 2 = Partial paralysis (total or near-total paralysis of lower face). 3 = Complete paralysis of one or both sides (absence of facial movement in the upper and lower face).
5. Arm motor: The limb is placed in	0 = No drift; limb holds 90 (or 45) degrees

the appropriate position: extend the arms (palms down) 90 degrees (if sitting) or 45 degrees (if supine). Drift is scored if the arm falls before 10 seconds. The aphasic patient is encouraged using urgency in the voice and pantomime, but not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic arm. Only in the case of amputation or joint fusion at the shoulder, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice.	 for full 10 seconds. 1 = Drift; limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed or other support. 2 = Some effort against gravity; limb cannot get to or maintain (if cued) 90 (or 45) degrees, drifts down to bed, but has some effort against gravity. 3 = No effort against gravity; limb falls. 4 = No movement. UN = Amputation or joint fusion, explain: 5a. Left Arm 5b. Right Arm
6. Leg motor: The limb is placed in the appropriate position: hold the leg at 30 degrees (always tested supine). Drift is scored if the leg falls before 5 seconds. The aphasic patient is encouraged using urgency in the voice and pantomime, but not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic leg. Only in the case of amputation or joint fusion at the hip, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice.	 0 = No drift; leg holds 30-degree position for full 5 seconds. 1 = Drift; leg falls by the end of the 5- second period but does not hit bed. 2 = Some effort against gravity; leg falls to bed by 5 seconds, but has some effort against gravity. 3 = No effort against gravity; leg falls to bed immediately. 4 = No movement. UN = Amputation or joint fusion, explain: 6a. Left Leg 6b. Right Leg
7. Limb ataxia: This item is aimed at finding evidence of a unilateral	0 = Absent.

cerebellar lesion. Test with eyes open. In case of visual defect, ensure testing is done in intact visual field. The finger-nose-finger and heel-shin tests are performed on both sides, and ataxia is scored only if present out of proportion to weakness. Ataxia is absent in the patient who cannot understand or is paralyzed. Only in the case of amputation or joint fusion, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice. In case of blindness, test by having the	1 = Present in one limb. 2 = Present in two limbs. UN = Amputation or joint fusion, explain:
 patient touch nose from extended arm position. 8. Sensory: Sensation or grimace to pinprick when tested, or withdrawal from noxious stimulus in the obtunded or aphasic patient. Only sensory loss attributed to stroke is scored as abnormal and the examiner should test as many body areas (arms [not hands], legs, trunk, face) as needed to accurately check for hemisensory loss. A score of 2, "severe or total sensory loss," should only be given when a severe or total loss of sensation can be clearly demonstrated. Stuporous and aphasic patients will, therefore, probably score 1 or 0. The patient with brainstem stroke who has bilateral loss of sensation is scored 2. If the patient does not respond and is quadriplegic, score 2. Patients in a coma (item 1a=3) are automatically given a 2 on this item. 	 0 = Normal; no sensory loss. 1 = Mild-to-moderate sensory loss; patient feels pinprick is less sharp or is dull on the affected side; or there is a loss of superficial pain with pinprick, but patient is aware of being touched. 2 = Severe to total sensory loss; patient is not aware of being touched in the face, arm, and leg.

9. Best language: A great deal of	0 = No aphasia; normal.
information about comprehension will be obtained during the preceding sections of the examination. For this scale item, the patient is asked to describe what is happening in the attached picture, to name the items on the attached naming sheet and to read from the attached list of sentences. Comprehension is judged from responses here, as well as to all of the commands in the preceding general neurological exam. If visual loss interferes with the tests, ask the patient to identify objects placed in the hand, repeat, and produce speech. The intubated patient should be asked to write. The patient in a coma (item 1a=3) will automatically score 3 on this item. The examiner must choose a score for the patient with stupor or limited cooperation, but a score of 3 should be used only if the patient is mute and follows no one-step commands.	 1 = Mild-to-moderate aphasia; some obvious loss of fluency or facility of comprehension, without significant limitation on ideas expressed or form of expression. Reduction of speech and/or comprehension, however, makes conversation about provided materials difficult or impossible. For example, in conversation about provided materials, examiner can identify picture or naming card content from patient's response. 2 = Severe aphasia; all communication is through fragmentary expression; great need for inference, questioning, and guessing by the listener. Range of information that can be exchanged is limited; listener carries burden of communication. Examiner cannot identify materials provided from patient response. 3 = Mute, global aphasia; no usable speech or auditory comprehension.
10. Dysarthria: If patient is thought to be normal, an adequate sample of speech must be obtained by asking patient to read or repeat words from the attached list. If the patient has severe aphasia, the clarity of articulation of spontaneous speech can be rated. Only if the patient is intubated or has other physical barriers to producing speech, the examiner should record the score as untestable (UN), and clearly write an explanation for this choice. Do not tell the patient why he or she is being tested.	 0 = Normal. 1 = Mild-to-moderate dysarthria; patient slurs at least some words and, at worst, can be understood with some difficulty. 2 = Severe dysarthria; patient's speech is so slurred as to be unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric. UN = Intubated or other physical barrier, explain:

11. Extinction and Inattention (formerly Neglect): Sufficient	0 = No abnormality.
information to identify neglect may be obtained during the prior testing. If the patient has a severe visual loss preventing visual double simultaneous stimulation, and the cutaneous stimuli are normal, the score is normal. If the patient has aphasia but does appear to attend to both sides, the score is normal. The presence of visual spatial neglect or anosagnosia may also be taken as evidence of abnormality. Since the abnormality is scored only	 1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities. 2 = Profound hemi-inattention or extinction to more than one modality; does not recognize own hand or orients to only one side of space.
if present, the item is never untestable.	

2401

2402

2403

2404

- 107

2405

2407 **13.4 Mori Classification**

2408

2409 The Mori classification, formulated on the basis of DSA, delineates the length and

2410 geometry of intracranial stenosis as follows:

2411

Туре	Descriptions
A	short (5 mm or less in length) concentric or moderately eccentric lesions less than totally occlusive
В	tubular (5 to 10 mm in length) extremely eccentric or totally occluded lesions, less than 3 months old
С	diffuse lesions (more than 10 mm in length), extremely angulated (>90°) lesions with excessive tortuosity of the proximal segment or totally occluded lesions, 3 months old or older

2412

2414 **13.5 TICI perfusion categories**

2415

The thrombolysis in cerebral infarction (TICI) grading system was described as a tool for determining the response of thrombolytic therapy for ischemic stroke. In interventional neuroradiology, it is commonly used for patients post endovascular revascularization. Like most therapy response grading systems, it predicts prognosis.

2420

Grade	Descriptions		
0	No Perfusion. No antegrade flow beyond the point of occlusion.		
1	Penetration With Minimal Perfusion. The contrast material passes beyond the area of obstruction but fails to opacify the entire cerebral bed distal to the obstruction for the duration of the angiographic run.		
2	Partial Perfusion. The contrast material passes beyond the obstruction and opacifies the arterial bed distal to the obstruction. However, the rate of entry of contrast into the vessel distal to the obstruction and/or its rate of clearance from the distal bed are perceptibly slower than its entry int and/or clearance from comparable areas not perfused by the previousl occluded vessel, e.g., the opposite cerebral artery or the arterial be proximal to the obstruction.		
	Only partial filling (<2/3) of the entire vascular territory is visualized.		
	2b	Complete filling of all of the expected vascular territory is visualized, but the filling is slower than normal.	
3	Complete Perfusion. Antegrade flow into the bed distal to the obstruction occurs as promptly as into the obstruction and clearance of contrast material from the involved bed is as rapid as from an uninvolved other bed of the same vessel or the opposite cerebral artery.		

2422 **13.6 ASITN/SIR collateral flow grading system**

2423

ASITN/SIR refers to American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR). The grading system scale is determined on DSA, classifying the cerebral collateral status ranging from grade 0 to 4. Grades 0-1, 2 and 3-4 are usually regarded as poor, moderate and good collateral flow.

2429

Grade	Descriptions	
0	No collaterals visible to the ischemic site	
1	Slow collaterals to the periphery of the ischemic site with persistence of some of the defect	
2	Rapid collaterals to the periphery of ischemic site with persistence of some of the defect and to only a portion of the ischemic territory	
3	Collaterals with slow but complete angiographic blood flow of the ischemic bed by the late venous phase	
4	Complete and rapid collateral blood flow to the vascular bed in the entire ischemic territory by retrograde perfusion	

2431

2432 2433

2434 2435

2436

CASSISS trial

CASSISS Study Protocol: Summary of Changes (Version 1.0 ⇒ Version 3.0)

CASSISS Study: China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis

				Pre	pared: May 1 ^s ', 201
#	Item	Page	Description of change(s)		Reasons for
			Before change (Version 1.0, date prepared: March 4 th , 2013)	After change (Version 3.0, date prepared: May 1 st , 2015)	change
1	Secon dary outco me	2. Summary (Page 9- 10) 3.5.2 Secondary objectives (Page 13) 6.2 Secondary endpoints (Page 21)	 Secondary outcome: Disabling stroke or death beyond 30 days through 3 years in both arms; Complication rates associated with stenting procedures; Restenosis (>50%) related to stenting within a follow-up of 3 years; Any stroke, severe TIA, or cardiovascular events within a follow-up of 3 years; National Institutes of Health Stroke Scale (NIHSS), mRS, and Barthel index assessment within a follow-up of 3 years; The compliance rate of the patients with regular medical therapy within a follow-up of 3 	 Secondary outcome: Disabling stroke or death after enrollment through 3 years in both arms; 2-year rate of the same-territory stroke; 3-year rate of the same-territory stroke; Any stroke, TIA, or cardiovascular events within a follow-up of 3 years. Death rate in both arms within a follow-up of 3 years. 	Due to content revisions

Prepared: May 1st, 2015

			years;Death rate in both arms within a follow-up of 3 years.		
2	Medica I therap y	4. Study design (Page 14) 6.7.1 Medical therapy (Page 24) 6.8.1 PTAS procedure (Page 26)	Medical therapy includes both aspirin 100 mg plus clopidogrel 75 mg per day for 90 days (aspirin 100 mg alone per day thereafter) and management of risk factors.	Medical therapy includes both aspirin 100 mg plus clopidogrel 75 mg per day for 90 days (aspirin 100 mg or clopidogrel 75mg alone per day thereafter) and management of risk factors.	Due to content revisions
3	Severe TIA	6.3 Definitions of endpoints (Page 22)	 Severe TIA refers to rapidly developed clinical signs of focal or global disturbance of cerebral function lasting longer than 10 minutes but fewer than 24 hours, without apparent nonvascular cause. 	Deleted	Due to content revisions

2437